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SUMMARY
Obsessive-compulsive disorder (OeD) is a common psychiatric condition
characterised by recurrent and disabling obsessions and compulsions. Although the
pathogenesis of the disease is unclear, studies have consistently provided evidence for
the involvement of genetic mechanisms. One strategy used to identify genetic
susceptibility factors has been case-control association studies between
polymorphisms in candidate genes and OeD.
Two prorrusmg Of'D candidate genes are those encoding catechol-O-methyl
transferase (eOMT) and the serotonin transporter (the COMT and SLC6A4 genes,
respectively). Association studies have implicated functional polymorphisms in
COMT and SLC6A4 (5-HTTLPR) in the development of OeD in various populations.
Futhermore, studies have shown that eOMT activity, which is regulated by oestrogen,
is under the control of oestrogen response elements (EREs). The ERE6 in the COMT
promoter has been shown to play an important role in hormone-dependent regulation
of COMT expression.
Immune-based theories of OeD pathogenesis have also been proposed. These stem
from the observed similarities between Oï.D and the immunological disorder
Sydenham's chorea (SC). Furthermore, patients with se or childhood onset OeD
have increased expression of the B-Iymphocyte marker, 08/17. However, despite
their possible phenomenological and psychobiological overlap, there have been no
extensive studies to investigate D8/17 expression levels in other anxiety disorders,
such as panic disorder (PD) or social phobia (SP) or putative Oï.D spectrum
disorders, such as trichotillomania (TTM).
Aim:
The aim of the present study was to use case-control association studies in the
genetically homogeneous Afrikaner sub-population to 1) reassess the roles in OeD
pathogenesis of the previously described functional polymorphisms in COMT and
SLC6A4; 2) determine if ERE6 is polymorphic, and, if so, to extend the association
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analysis using this variant and 3) assess the role of D8/17 in development of OCD,
PD, SP and TTM.
Methods:
All case and control subjects were of Afrikaner descent and underwent a structured
clinical interview, following their informed consent to take part in the study. The
polymorphisms in COMF and SLC6A4 were genotyped following published methods
based on polymerase chain reaction (PCR) amplification of specific exons and
restriction enzyme (COM!) or direct fragment size analysis (SLC6A4) of the products.
Oligonucleotide primers were designed to amplify a 150 base pair fragment of the
COMF promoter region containing ERE6, which was screened for sequence variation
using PCR- single strand conformational polymorphism (SSCP) analysis. Fragments
showing mobility shifts were sequenced using an automated sequencer (University of
Stellenbosch). Genotype data was analysed by Chi-square analysis using the SPSS
software package.
Analysis of D8/17 expression was by indirect immunofluorescence assay. B cell were
labelled with D8/17 antibody and fluoresced with antimouse IgM and DR HLA class
staining. The cells were then analysed by flow cytometry. D81l7 data was analysed
using analysis of variance (ANOVA) and the post-hoc Tukey procedure was used to
correct for multiple testing.
Results:
A statistically significant association was shown between COMF and OCD, but not
between SLC6A4 (5-HITLPR) and the disease. A meta-analysis, pooling the results of
5-HTFLPR genotyping in the present study and that of a study conducted in a North
American population, also generated no significant result. A single nucleotide
polymorphism (SNP) was detected 8 bases 5-prime to ERE6 in COMF, but did not
show association with OCD development.
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Expression levels of the B lymphocyte marker 08/17 revealed no significant
association with OCD or TIM subjects, when compared to controls. Nor were
differences observed when the OCD group was stratified according to age of onset, or
history of various comorbid disorders. However, the PD/SP group had significantly
lower levels of 08/17 expression than the other groups.
Conclusion:
Case:control association studies frequently produce discrepant results. The data
generated in the present study supports a role for COMJ'in the development of OCD,
but provides evidence that S"LC6A4 may not playa significant role. Furthermore, the
previously reported association of OCD with higher levels of 08/17 expression may
not be general and may be related to the age of onset of the disease. The lower levels
reported in the present study in the PD/SP group warrants further investigation.
Identifying gene variants and other factors that play a significant role in the
development of OCD is important for the design of further studies to understand the
molecular pathophysiology of the disease. In tum, it is envisaged that this will lead to
better patient management and treatment strategies.
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Agtergrond:
Obsessiewe kompulsiewe steuring(OKS) is 'n algemene psigiatriese kondisie /
toestand wat gekarakteriseer word deur herhaaldelike obsessies en konpulsies.
Alhoewel die oorsaak van die toestand nie bekend is nie, het studies herhaaldelik
bewys dat genetiese faktore 'n rol speel. Hierdie genetiese faktore word onder andere
geidentifiseer deur assosiasie studies (gevalle vs kontroles) tussen polimorfismes in
kandidaat gene en OKS.
Die gene wat onderskeidelik kodeer vir katesjol-O-metieltransferase (COMT) en die
serotonien draer (die COMF en SLC6A4 gene onderskeidelik), is gei
dentifeseer as twee belowende kandidaat gene. Assosiase studies het geimpliseer dat
funksionele polimorfismes in COMF and SLC6A4 (5-HTTLPR) 'n rol gespeel het in
die onstaan van OKS in verskeie populasies. Studies het ook aangetoon dat COMT
aktiwiteit, wat gereguleer word deur estrogeen, onder beheer is van estrogeen respons
elemente (EREs). Die ERE6 in die COMT promotor speel 'n belangrike rol III
hormoon-afhanklike regulasie van COMT uitdrukking/ekspressie.
Daar is ook voorstelle van immuun gebasseerde teorïee van OKS patogenese. Dit
spruit uit die ooreenkoms tussen OKS en die immunologiese afwyking Sydenham-
chorea (SC). Daar is ook waargeneem dat pasïente met SC of OKS, met aanvang in
kinderjare, 'n verhoogde uitdrukking het van die B-lirnfosiet merker D8/17. Ten
spyte van 'n moontlike fenotipiese en psigobiologiese ooreenkoms, is daar nog geen
deeglike studies gedoen om 08/17 uitdrukkingsvlakke in ander angsafwykings,
naamlik paniek afwyking (PA) of sosiale fobia (SF), of moontlike OKS spektrum
afwykings soos trigotillomanie (TTM), aan te dui nie.
Doelwit:
Die doel van hierdie studie was om geval-kontrole assosiasie studies aan te wend in
die geneties homogene Afrikaner sub-populasie om 1) die rolle van die voorheen
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beskryfde funksionele polimofismes in COMT en SLC6A4 te ondersoek; 2) om te
bepaal of ERE6 polimorfies is, en indien wel, om die assosiasie analises uit te brei
deur gebruik te maak van die polimorfisme en 3) om die rol van D8/17 te bepaal in
die ontwikkeling van OKS, PA, SF en TIM.
Metodes:
Alle gevalle en kontrole pasïente was van Afrikaner afkoms en het, na ingeligte
toestemming om deel te neem aan die studie, 'n gestruktureerde kliniese onderhoud
ondergaan. Die polimorfismes in eOMT en SLC6A4 is gegenotipeer deur gebruik te
maak van gepubliseerde medtodes. Hierdie metodes was gebaseer op die polimerase
ketting reaksie (PKR) amplifikasie van spesifieke eksons gevolg deur restriksie
ensiem verterings (COMl) of direkte fragment grootte analises (SLC6A4) van die
PKR produkte. 'n EEN honderd en vyftig basis paar fragment van die COMT
promotor area bevattende ERE6 is geamplifiseer deur gebruik te maak van spesifieke
oligonukleotied inleiers. Hierde fragment is geanaliseer vir nukleotiedvolgorde
variasie deur gebruik te maak van PKR enkelstring konformasionele polimorfismes
(SSCP's). Fragmente wat 'n verandering in grootte getoon het se nukleotiedvolgorde
is bepaal deur gebruik te maak van 'n outomatiese nukleotiedvolgorde bepaler
(Universiteit van Stellenbosch). Genotipiese inligting is geanaliseer deur Chi-
kwadraat analises deur gebruik te maak van die SPSS sagteware pakket.
D81l7 uitdrukking is geanaliseer deur direkte immunof1uoressensie toetse. B- selle is
gemerk met 08/17 antiliggame en gefluoriseer met anti-muis IgM en DR HLA klas
kleuring. Die gemerkte selle is geanaliseer deur gebruik te maak van vloeisitometrie.
Die 08/17 data is geanaliseer deur gebruik van ANOVA, en die post-hoc Tukey
prosedure is gebruik om veelvoudige toetse te korrigeer.
Resultate:
'n Statisties beduidende assossiasie is aangetoon tussen eOMT en OKS, maar geen
assossiase is aangetoon vir SLC6A4 (5-HTTLPR) en OKS nie. Meta-analises, 'n
kombinasie van die resultate van 5-HTTLPR genotipering in hierdie studie en van 'n
studie in 'n Noord-Amerikaanse populasie, het geen betekenisvolle resultate
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opgelewer nie. 'n Enkel- nukleotied polimorfisme (ENP) is waargeneem 8 basisse
van die 5' van ERE6 in COMT, maar het geen assosiasie getoon in die ontwikkeling
van OKS nie.
Geen beduidende assosiasie IS aangetoon ID die uitdrukkingsvlakke van die B-
limfosiet merker 08/17 tussen OKS en TIM pasïente en kontroles nie. Verkleining
van die OKS groep, deur gebruik te maak van aanvangs ouderdom of geskiedenis van
verskeie ander afwykings het ook geen verskille opgelewer nie. Die PA/SF groep het
egter beduidende laer vlakke van 08/17 uitdrukking as die ander twee groepe.
Gevolgtrekking:
Gevalle:kontrole assosiasie studies lewer in baie gevalle teenstrydige resultate. Die
inligting wat gegenereer is in hierdie studie dui op 'n rol vir COMT in die
ontwikkeling van OKS, maar dien ook bewyse dat SLC6A4 nie 'n beduidende rol
speel nie. Die voorheen beskryfde assosiasie tussen OKS en hoër uitdrukkingsvlakke
van 08/17 is moontlik nie 'n algemene verskynsel nie, en mag verband hou met die
aanvangsouderdom van die afwyking/toestand. Die laer uitdrukkingsvlakke van
08/17 in hierdie studie vir die PA/SF groep noodsaak verdere navorsing.
Identifisering van geen polimorfismes and ander faktore wat 'n rol speel in die
ontwikkeling van OKS is belangrik vir verdere navorsing om die molekulêre
patofisiologie van die afwyking te verstaan. Die resultate sal ook aanleiding gee tot
beter hantering van pasrente en nuwe behandeling strategïee.
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3CHAPTER 1 : INTRODUCTION
1.1. Genetics and psychiatry
Many diseases run in families, but that, in itself, is not enough evidence to invoke the
involvement of genes, since infection and environmental factors may also be familial.
However, the use of studies of adopted siblings and of twin pairs provides evidence
for genetic involvement in familial diseases. Such adoptive studies have shown that
the risk of an adopted child developing a psychiatric disorder is significantly more
dependant on the mental health of the biological parents than that of the adoptive
parents (Kendler and Diehl, 1993).
In twin studies, the investigative strategy is to compare the concordance rate, that is
the chance of both twins being affiicted with the same disorder, among monozygotic
and dizygotic twin pairs. If the concordance rate for a particular disorder is similarly
high for both mono- and di-zygotic twin pairs, a shared environment is likely to be the
major factor inferring disease susceptibility, while a similarly low concordance rate
would suggest similar, non-shared environmental conditions to be the major factor. A
genetic component for disease is implicated when the concordance rate for
monozygotic twins is significantly higher than for dizygotic twins. If only one gene
contributes to the disorder in a family, the concordance rate for monozygotic twins
would be two-fold higher than in dizygotic twins.
Twin study data have implicated genetic factors in a variety of psychiatric disorders
(Plornin, 1994). The concordance rates generated indicate that some psychiatric
disorders may have a stronger genetic component than many other complex diseases,
although generally the concordance rates between monozygotic and dizygotic twins
are less than two-fold, suggesting that both genetic and shared environmental factors
contribute to the disorder (Plomin, 1994).
1.1.1. Many psychiatric diseases are multifactorial disorders.
Multifactorial disorders are disorders which are caused by the interaction of a variety
of susceptibility genes and environmental factors. Diabetes mellitus, cancer and
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4schizophrenia are examples of multifactorial disorders which run in families, but have
a rather complex pattern of inheritance (Carter, 1972).
With the availability of detailed genetic maps in humans, and many other organisms
(Hudson, 1998), various strategies have been developed to unravel the complex
genetic basis of multifactorial diseases. Many of these methods have been used in
identifying possible genetic loci for the development of psychiatric disorders such as
schizophrenia (Bailer et aI., 2000; Brzustowicz et aI., 2000), Tourette's syndrome
(TS) (Barr et aI., 1999) and bipolar affective disorder (Detera-Wadleigh et aI., 1999;
Friddle et aI., 2000). These molecular genetic strategies and their application to
psychiatric disorders will be discussed briefly in the following section.
1.1.2. Genetic search strategies!
1.1.2.1.Parametric linkage analysis
Linkage analysis is the first step in positional cloning, which is a two-step genetic
search strategy to find disease-causing genes. This method is used to identify alleleie
variations of genes or genetic markers of known location that are co-inherited with the
disease-causing gene and thus are located on the same chromosomal segment
(reviewed by Keating, 1992). When performing linkage analysis, it is important,
firstly, to identify a suitable family, in which the disease is segregating with a known
mode of inheritance. Secondly, the phenotype of the disease must be carefully
classified in the family members. This is crucial in linkage analysis, since this
technique deals with the comparison of genotype and phenotype and an incorrect
diagnosis could lead to incorrect interpretation of linkage data. (reviewed by Keating,
1992). Careful genotyping of each family member using deoxyribonucleic acid
(DNA) markers of known position is then performed. Currently, the most commonly
used DNA markers are short tandem repeats (STR). These STRs are simple sequences
that are repeated a variable number of times, resulting in length differences that are
polymorphic and stably inherited. The most commonly used STRs are the
dinucleotide CA repeats, which are spaced on average every 50000 base pairs (bp)
throughout the genome (Weissenbach et aI., 1998).
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gene on, for example, chromosome 6, then all affected members of the family used in
the study should carry an identical region of chromosome 6 around that mutant allele
(identity by descent) (fig 1). The chromosomal locus of a disease-causing gene
mutation is mapped by determining genetic linkage, or co-inheritance, between the
inheritance of disease within a family and DNA markers of known chromosomal
location. If a DNA marker is closely linked to the disease-causing gene, affected
individuals in the family would be expected to inherit the same allele of the ONA
marker from an affected parent (fig 1 allele b). It: however, the marker is on the same
chromosome, but distant from the disease-causing gene, the alleles at the marker locus
will sometimes be separated from the disease-causing gene during meiotic
recombination (fig 1. TI-3 allele A). The further away the marker from the disease-
causing mutation, the more often recombination events occur. Therefore, the rate of
recombination is a measure of distance on a chromosome between the marker and the
disease causing mutation (reviewed Burmeister, 1999). If two loci are less than 1
eentimorgan (cM) (1cM=approximately 1 million base pairs) apart, their alleles are
co-inherited 99% of the time. However, if two loci are 50 cM or more apart, their
alleles are co-inherited in only 50% of individuals with the disease, which is equal to
free recombination.
Computational analysis is used in linkage studies to identify co-segregation of the
alleles of a marker of known chromosomal location and a locus that causes disease
within a family. These linkage programmes analyse the genotype:phenotype data of
the family members and calculate the odds that a DNA marker and disease gene are
linked, ie., they are co-inherited more often than would be expected by chance
(reviewed by Burmeister, 1999). These odds are represented in a logarithmic form
known as the LOD (logarithm of odds) score. A lod score of +3, which represents
odds of 1000: 1, is considered as good evidence for linkage, whereas a LOD score of
2, which represents odds of 1:100, means that a locus can effectively be excluded.
(reviewed by Burmeister, 1999)
Locus heterogeneity, which is when the same clinical disease in different families is
caused by mutations in different genes, is a major complication in linkage mapping. A
prime example of this is inherited deafness, for which over 30 different loci have been
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6identified (Petit, 1996). Linkage analysis for genetically heterogeneous, multilocus
disorders such as deafness is usually established in single large families studied one
family at a time. Alternatively, families living in remote areas, or in cultural isolation
are studied, where only one deafness gene may be present and the population
represents a large extended pedigree. This approach was effectively used in the field
of psychiatric genetics in the study of bipolar affective disorder in Costa Rican and
Amish populations (Freimer et al., 1996; Ginns et al., 1996).
Once linkage analysis has localised a gene to a specific chromosomal region, it may
be isolated by cloning the region (positional cloning) (Botstein et al., 1980), although,
more recently, sequence and related information generated by the Human Genome
Project often obviate this step (Cheung et aI., 2001). Subsequently, the gene, its
mutations and the protein product it encodes can be identified (reviewed by Marian
and Roberts, 1995).
1.1.2.2. Non-parametric linkage analysis
The success of linkage analysis is largely due to the fact that in monogenic disorders
the mode of inheritance is known. To avoid some of the problems of selecting a
specific mode of inheritance for complex disorders, while still employing some of the
power of linkage analysis, non-parametric linkage analyses, which are mode-of-
inheritance-independent, methods were developed. One such method is affected sib
pair (ASP) or, more generally, affected pedigree member (APM), analysis. In this
method, only sibpairs or other pairs of affected relatives are studied. This, however,
means that the power of observing alleles segregating in large families is lost. The
basis behind this strategy is that, independently of whether a disease is dominant,
recessive or complex, if there is a disease-causing mutation in a specific chromosomal
region, two affected members of a family can be expected to share an allele of a
marker in a gene involved in disease development, or adjacent to it, more often than
can be expected by chance. With this method, one is able to design studies that
include very specific diagnosis, eg, only bipolar I disorder with exclusion of bipolar
II within a family, thus avoiding unclear phenotypes. Also, no genetic model of the
disease needs to be specified and linkage can be detected in the presence of genetic
heterogeneity (reviewed by Burmeister 1999)
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Fig 1: Linkage analysis and recombination. Individuals indicated by a solid symbol
are affected with dominant disease due to the presence of disease allele D. N allele is
the normal allele at this locus. Most affected offspring inherit allele A and b at the
flanking marker from their affected father because these alleles are linked to disease-
causing allele D. Individualll-3 shows a recombination event, in which allele A was
separated from the disease causing allele. The more tightly linked alleles A and b are
to the disease-causing gene, the less likely the chances of recombination. Thus,
recombination frequency is the measure of the distance markers and the disease-
causing gene. Squares and circles represent male and female, respectively. (Adapted
from Burmeister, 1999).
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81.1.2.3. Case-Control Association studies
Both parametric and non-parametric linkage analyses are based on following marker
alleles that are close to a disease-causing mutation on a chromosome though a family.
They are therefore family-based and rely on a number of affected individuals within a
two or multi-generation family. Linkage analysis can be conducted with no
knowledge of pathophysiology of the disorder and is therefore not hypothesis driven.
When a chromosomal region is shown to be linked to a phenotype, it may be quite
extensive and may contain hundreds of genes. The ultimate identification of the
variants that are contributing to the disease phenotype may be laborious and resource
intensive (reviewed by Malhotra and Goldman, 1999).
The disadvantage of using parametric linkage analysis in identifying genes involved
in complex disorders includes the necessity to specify a genetic model, the difficulties
involved to identify large families with multiple affected individuals and the low
power to detect genes of small effect.
In contrast to linkage analysis, association studies are methods that are able to identify
susceptibility genes in a more direct manner, using knowledge of the disease
pathogenesis. These studies rely on the hypotheses of the molecular causes of the
disorder being investigated and, unlike linkage analysis, they are not necessarily
family-based. In association studies, an individual is the basic unit of analysis and no
knowledge of the genetic mode of inheritance is needed. Therefore, these studies are
well-suited to investigate genetic influences in complex disorders.
Genetic case-control association studies compare the frequency of alternative
polymorphic forms (alleles) of a specific candidate gene within a patient group with
that of a control group, with statistical support provided. The generation of a
statistically significant difference between allele frequencies and genotype
distribution in patient and control groups suggests either a causative role for a
functional polymorphism tested or the presence of another functional variant in the
same gene or in a linked one. Since psychiatric disorders are common and it is
assumed that multiple genes playa role in the development of these disorders, the
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9predisposing alleles are expected to be fairly common polymorphisms rather than rare
mutations (Burmeister et aI., 1999).
When designing genetic case-control association studies, many factors need to be
taken into account. As the present study utilizes this method, the following sections
will deal with some of these factors.
Selection of subjects
One major pitfall of case-control association studies is the potential for ethnic
stratification between subjects. If a particular allele occurs at a different frequency
across ethnic groups and cases and controls are not precisely ethnically matched, one
might find differing allele frequencies between the two groups, thus observing an
association with the phenotype of interest that, in fact, does not exist (reviewed by
Malhotra and Goldman, 1999).
One method to control for genetic complexity among population groups is to conduct
association studies in ethnically homogeneous population groups. Populations that are
either physically or culturally isolated are frequently also genetically isolated
(Sheffield et aI., 1998). The present study makes use of the Afrikaner sub-population
of South Africa.
The Afrikaner sub-population was formed by a group of European immigrants,
primarily of Dutch, German and French descent, who began settling in Cape Town in
1652 (Torrington et aI., 1984; Jenkins, 1990). At the turn of the is" century, there
were 1265 Europeans in Cape Town. In the 18111 century, European immigration to
South Africa was small and by the first half of the 19th century, the Afrikaners began
the "Great Trek", which were a series of migrations of Europeans away from the
coastal regions to establish farming communities in the interior of the country
(Simonie et al., 1998). The lack of large waves of immigration from Europe to South
Africa, coupled with the "Great Trek" and the small number of original founders, has
lead to the relative homogeneity of the Afrikaner sub-population. Furthermore, the
early geographical isolation of the Afrikaner settlements and the cultural isolation of
the sub-population, mainly due to the Afrikaans language and the religious beliefs
(Dutch Reformed), further contributed to their homogeneity.
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As discussed above, conducting association studies in homogeneous population
groups is a way to overcome the problem of genetic complexities between different
populations. Another way to overcome this population stratification problem in case-
control studies is by using family-based approaches known as haplotype relative risk
(HRR) and transmission disequilibrium test (TDT) (Fig2 b-d)
In HRR the alleles that are not transmitted to the affected child by the parents are
used as control samples (Falk and Rubinstein, 1987; Terwilliger and Ott, 1992)
(fig2c). A 2x2 contingency table is made of allele frequencies in the proband and
controls and, by using chi-square (X2) analysis, the presence or absence of a
significant difference between the two groups is determined. The disadvantage of this
method is that no distinction is made between probands homozygous or heterozygous
for a particular marker in affected and unaffected individuals.
The basis for TOT is the use of a family with one or more affected offspring where at
least one of the parents is heterozygous for the marker suspected of being involved the
disease. It is expected that one of the marker alleles will be transmitted to the affected
child and one not. The TDT compares the frequency of transmitted versus non-
transmitted parental alleles by using X2 analysis (Spielman and Ewens, 1996) using the
non-transmitted allele from the parents of an affected child as an internal control (fig
2b).
Selection of candidate genes and polymorphisms
Candidate genes are selected for their possible involvement in the disease pathology.
Firstly, a candidate gene can be identified by its position in a chromosomal area that
has been implicated in prior linkage studies. Alternatively, a candidate gene can be
selected, irrespective of position, based upon evidence that the gene plays a role in the
pathophysiology of the disease. In the study of neuropsychiatric disorders, many
candidate genes are chosen based on research implicating specific systems, of which
their gene products form part, in a specific condition (reviewed by Malhotra and
Goldman, 1999).
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Population based case-control association studies
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Fig 2 Categories of association studeis. (A) Case-control association compares
genotype distribution and allele frequencies of patient and appropriately matched
control group. The figure clearly shows that allele A occurs more frequently in the
patient group than in the control group. (8) Family based association studies use non-
transmitted alleles (shown in red) as control samples. (C) HRR uses non-transmitted
alleles (shown in red in 2B) from parents as controls. (D) TDT compares the
frequency of transmitted and non-transmitted parental alleles from heterozygous
parents (Adapted from Burmeister 1999).
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After selecting an appropriate candidate gene, the next step is to select a suitable
variation (or polymorphism) within the gene to test the association. Most genes
contain a number of sequence variations. The selection of an appropriate sequence
variant is crucial in the design of case-control association studies and several factors
need to be taken into consideration.
Firstly, it is important to determine the frequency of the allele (reviewed by Malhotra
and Goldman, 1996). Studies have shown that the polymorphic variants with low
frequencies of one allele may provide little statistical power to detect significant
associations unless the study group's size is large enough, or the variant has a strong
influence on phenotype.
Secondly, the number of alleles at a specific locus also needs to be taken into account.
Variants with several relatively frequent alleles provide a number of potential
genotypes, thereby increasing the informativeness of the locus, but complicating the
statistical analysis (Chang et al., 1996).
Thirdly, the functionality of the selected polymorphism must also be considered.
Generally intronic sequence variants do not affect gene splicing or gene expression.
Many naturally occurring sequence variants have been identified within the coding
region of genes, but again this does not necessary alter gene expression or amino acid
sequence (reviewed by Malhotra and Goldman, 1996) Association studies employing
non-functional polymorphisms have a significantly lower prior probability of
detecting valid associations, than studies using functional variants (reviewed by
Malhotra and Goldman, 1996). Although they may indicate the presence of a closely
linked functional polymorphism, positive findings with non-functional variants may
be as a result of inadvertent ethnic stratification of cases and controls. Thus, the most
critical criterion in selecting a candidate polymorphism within a candidate gene is the
careful examination of the functional effects of each variant.
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Sample size and statistical power
In order to successfully analyse association studies, the sample size and statistical
power of the study need to be carefully evaluated. In designing these studies, the
sample size needs to be sufficiently large to create enough statistical power to reduce
the probability of generating false-positive associations (Type I errors) (Berry el aI.,
1998). In cases where association studies may lack sufficient power to prove or
disprove an association, a meta-analysis can be performed. A meta-analysis is a
statistical procedure that integrates the results of several independent studies of a
particular disease provided that the investigators 1) have followed the same diagnostic
criteria, 2) followed the same methodology and 3) have conducted the study in
sufficiently similar population groups.
The ability to conduct a successful meta-analysis relies on the availability of all the
relevant data. The inclusion of only a subset of all the available data in a meta-
analysis may introduce biases and threaten its validity. This is a major disadvantage of
meta-analyses since many studies, especially negative association studies, remain
unpublished. Other studies may have limited distribution, or may be published in
journals not currently on the bibliographical databases, making their detection and
inclusion into a meta-analysis rather difficult (McAuley et aI., 2000).
In summary, there are many factors to take into account when designing case-control
association studies. It is firstly very important to choose a suitable patient group and a
ethnically well-matched control group. Failure to do this could lead to spurious results
because of genetic stratification among population group. The effect of population
stratification can be minimized by the used of genetically homogeneous populations
or employing family-based association studies. Secondly, care should be taken when
selecting a specific candidate gene, as well as candidate polymorphism within the
selected candidate gene. Candidate genes should be chosen on the basis of knowledge
of disease pathology and candidate polymorphisms should preferably have a
functional effect on the gene product. Finally, the sample size and statistical power of
the study should be sufficiently large in order to reduce the risk of false associations.
Investigations of the molecular causes of psychiatric disorders has often produced
controversial or non-reproducible results (Burmeister, 1999). As the present study will
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involve association studies to delineate the role of certain candidate genes in the
pathogenesis of obsessive-compulsive disorder (OCD), the following section of this
review will discuss OCD in some detail.
1.2. OBSESSIVE-COMPULSIVE DISORDER
Obsessive-compulsive disorder has been described as a prevalent, disabling
psychiatric disorder (Murray and Lopez., 1996). It is characterised by recurrent
obsessions or compulsions that are time consuming, ie., take more than one hour per
day, or are severe enough to cause marked distress or significant social and work
impairment.
Obsessions are persistent ideas, thoughts, impulses or images that are experienced as
intrusive and inappropriate and that cause marked anxiety and distress. The most
common obsessions are: i) repeated thoughts about contamination, eg., being
contaminated by shaking hands with another person, ii) repeated doubts, eg.,
wondering whether one has performed some act, such as having hurt someone in a
traffic accident or not having turned off the stove at home, iii) a need to have things
arranged in a particular order, eg., intense distress when objects are not ordered or
symmetrical, iv) aggressive impulses, eg., recurrent thoughts of hurting one's own
child and sexual imagery, eg., a recurrent pornographic thought.
Compulsions are repetitive behaviours or mental acts, which a sutTerer is driven to
perform to reduce or prevent anxiety and distress often caused by obsessions. Adults
sutTering from OCD, at some point during their illness, recognise that their obsessions
or compulsions are excessive or unreasonable. This, however, does not apply to
children, since they lack significant cognitive awareness to make this judgement.
A number of clinical syndromes and OCD overlap in terms of phenomenological
factors, clinical course and treatment. These disorders form a distinct category of
inter-related disorders referred to as obsessive-compulsive (OC) spectrum disorders
and may share a common pathophysiologic and genetic basis with OCD (Hollander,
1993; Rasmussen, 1994; McElroy et aI., 1994).
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Obsessive-compulsive (OC) spectrum disorders
Obsessive-compulsive spectrum disorders include impulse control disorders (eg.,
trichotillomania [TTM], pathological gambling and compulsive buying), somatoform
disorders (eg., body dimorphic disorder), eating disorders (eg, anorexia and binge
eating), compulsive sexual disorders, Tourettes syndrome (TS) and other movement
disorders (reviewed by Ravindran, 1999).
The phenomenological similarities between OCD and OC spectrum disorders have
been well documented (McElroy et aI., 1994; Hollander and Benzaquen, 1997). These
similarities include the nature and content of thoughts, the associated distress caused
by these thoughts, the frequent self-evaluation and the demand for reassurance
(reviewed by Rivindran, 1999).
Obsessive-compulsive spectrum disorders, like OCD, often have onset in childhood or
early adult life. Comorbidity data is perhaps the strongest evidence for a link between
OCD and OC spectrum disorders (Barsky et aI., 1986; Hollander, 1993; Rubenstein et
aI., 1993) and there have been reports of high rates of OC spectrum disorders in
patients with OCD (Rasmussen and Tsuag, 1987; Tamburrino et aI., 1994). Further
support for this comes from the reports on high rates of OCD in family members of
probands with OC spectrum disorders (Pauls et aI., 1995).
The pathophysiology of OCD spectrum disorders still remains unclear, and it has been
proposed that they form an overlapping, but heterogeneous group, of disorders with
multifactorial aetiology (Rasmussen, 1999).
1.2.1. THE DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS (4TH ED) DIAGNOSTIC CRITERIA FOR OCD
The Diagnostic and Statistical Manual of Mental Disorders (4th Ed) (DSM-IV)
(American Psychiatric Association, 1994) is the diagnostic tool most frequently used
in the clinical diagnosis of mental disorders, including OCD. The criteria for OCD, as
laid out in the DSM-IV, define OCD in terms of its characteristic symptoms and not,
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as in the case with depression, in terms of a syndrome. The diagnostic criteria for
OCD defined by the DSM-IV are as follows:
The obsessions must be recurrent or persistent or the images, which are experienced,
must be intrusive and inappropriate. They should also cause marked distress and
anxiety. The intrusiveness should be greater than that experienced by normal worry.
The obsessions and compulsions must be a product of the patient's own mind and not
due to an outside stimulus (this excludes thought insertion or schizophrenia). The
patient must attempt to suppress or ignore these obsessions or attempt to neutralize
them with some other thought or action.
The DSM-IV defines compulsions as repetitive mental acts or behaviour which a
patient is driven to perform in response to an obsession or according to rules that must
be very strictly applied. The repetitive behaviours or mental acts must be performed in
order to reduce or prevent anxiety or prevent some feared event or situation; they
should, however, be clearly excessive or have no real connection to the anxiety that
they are intended to neutralise.
At some point during the illness, the patient should recognise that the obsessions and
compulsions are excessive or unreasonable. These obsessions and compulsions should
also be time-consuming, i.e., more than 1 hour a day or significantly interfere with the
patient's normal functioning. The DSM-IV also excludes a diagnosis of OCD in the
presence of another Axis I disorder. So, if a patient with affective disorder
experiences an obsessive component that is clearly depressive and completely
constrained within the duration of affective disorder, this would not be regarded as
OCD. Moreover, there are cases in depression where a patient experiences intrusive
images that are obsessional in nature, but that are clearly related to the depression.
1.2.2. EPIDEMIOLOGY OF oen
A number of studies have attempted to determine the prevalence of OCD. These
studies can be divided into the earlier studies in which diagnosis of OCD was solely
based on clinical judgement and the modern studies, in which structured or semi-
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structured instruments were used in the diagnosis. Roth and Luton carried out the first
of the earlier studies in Tennessee in 1942 (Roth and Luton, 1942). In their study, it
was found that 0.3% of 1700 people in the sample had a condition that would be
diagnosed as OCD. Brunetii in France carried out a second study in 1977. In this
study, again, only clinical judgement was used and it was revealed that approximately
1% of the population had OCD (Brunetti, 1977).
More recent surveys have identified OCD patients using standardised diagnostic tools.
These studies can be divided into three groups:
1. The 14 worldwide studies based on the Present State Examination (PSE)
(reviewed by Wing et aI., 1974).
2. Studies based on the Diagnostic Interview Schedule (DIS), of which the most
significant are the Epidemiological Catchments Area (ECA) surveys carried
out in the United States in the 1980's (Robbins and Reiger., 1991).
3. The British National Survey of Psychiatric Morbidity (Jenkins et aI., 1997,
Meltzer et al., 1995).
Overall results from these epidemiological surveys suggest that OCD is prevalent in
approximately 2-3% of the population, which makes it more common than
schizophrenia (1%) and less prevalent than depressive disorders (Kamo et al., 1988).
1.2.3. TREATMENT OF oen
Patient response to a variety of pharmacological treatments for OCD has given
investigators clues concerning metabolic pathways, which may be involved in OCD
pathogenesis. The drugs that are used in OCD treatment target a variety of proteins
and enzymes involved in neurotransmission. The targets of these medications also
serve as ideal candidate genes for OCD susceptibility. Furthermore, the pathways they
act upon may also harbour many strong candidate genes. For these reasons, the
following sections will deal with the pharmacological treatment ofOCD.
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1.2.3.1. Pharmacotherapy
Manipulations of serotonin (5-HT) are pivotal in pharmacological treatment of OCD.
Drugs used in the treatment ofOCD typically act by increasing 5-HT levels within the
nerve-synapse in one of four ways: (i) by increasing 5-HT synthesis, (ii) inhibiting the
reuptake of 5-HT from the presynaptic neuron, (iii) increasing the release of 5-HT
from the presynaptic neuron and (iv) inhibiting the metabolism of 5-HT in the
presynaptic neuron.
Selective serotonin reuptake inhibitors
Several placebo-controlled studies have demonstrated the efficacy of selective
serotonin reuptake inhibitors (SSRIs) (Chouinard et al., 1992; Goodman et al., 1989)
in OCD and other anxiety disorders such as panic disorder (PD) and social phobia
(SP) (Davidson, 1998; Katzelnick et al., 1995; Taylor, 1998). It is believed that the
therapeutic effects of SSRIs are to block the serotonin transporter (5-HTT) protein,
responsible for the reuptake of 5-HT into the presynaptic neuron, leading to an
increase in synaptic levels of 5-HT. This, in turn, leads to an increase in the
stimulation of 5-HT receptors (5-HT2 and 5-HTla) on the post-synaptic neurons on a
variety of brain regions. It is this cascade of events that is believed to lead to the
improvement of symptoms.
Potent SSRIs such as fluoxitine, paroxetine and fluvoamine have been well
established as the monotherapy of choice for OCD. These drugs are well tolerated by
patients, even in large doses. Fortunately, when one SSRI fails to improve symptoms,
several others are available and may be beneficial.
Tricyclic antidepressants
Tricyclic antidepressants (TCA) have been extensively studied in a wide variety of
anxiety disorders (Casacalenda and Boulenger, 1998; Lydiard et al., 1996; Taylor,
1998). Clomipramine, which is a potent 5-HT selective TCA, has been found to be
effective in the treatment of OCD (The Clomipramine Collaborative Study Group,
1991; De Veaugh-geiss, 1993). Studies comparing the efficacy of clomipramine and
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SSRls have shown that clomipramine may be slightly more effective than SSRls in
the treatment of OCD, but this benefit is offset by an associated increase in the
incidence of adverse side-effects (Carpenter et al., 1996).
Administration of medication
The first step in treating OCD patients is to make a positive diagnosis according to
DSM- Yl criteria (Appendix lY). Current evidence suggests that OCD is commonly
misdiagnosed and therefore often left untreated (Stein, 2000). Also, various disorders
with intrusive symptoms, such as post traumatic stress disorder or generalised anxiety
disorder, are often misdiagnosed as OCD (Stein, 1996).
Once a DSM-lY diagnosis of OCD is made, certain complications need to be
considered as they may have an effect on the pharmacotherapy of OCD. The severity
of symptoms needs to be assessed as patients with severe symptoms may require
hospitalisation in order to help contain symptoms.
Comorbid medical disorders and medication is another complication that needs to be
considered when treating OCD patients. Clinicians need to be aware of the multiple
interactions between medications that are used in the treatment of OCD and other
medical disorders. Fortunately, SSRIs have relatively few interactions with other
medications (Leonard, 1997). Many patients with TS, a disorder characterised by
vocal and motor tic, frequently suffer from comorbid OCD. Although the comorbid
OCD may respond to conventional OCD treatment, additional medication that targets
the tics is necessary to relieve many symptoms of TS (Swedo and Leonard, 1994).
During pregnancy, lactation and menopause, pharmacotherapy should ideally be
avoided. However, where clinical considerations outweigh the risk of medication,
such intervention is considered only after consultation with a specialist Studies have
shown that fluoxitine is relatively safe during pregnancy (Nulman and Koren, 1997).
For reasons, such as those outlined above, the first line of medication in OCD
treatment is SSRls. The safety and efficacy of SSRls has been well established with
studies showing that up to 50% of patients respond to these agents (Hirschfeld, 1999).
When SSRI treatment is successful in a particular patient, treatment is maintained for
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at least one year. The maintenance dose of SSRl required may be slightly lower than
is required for acute treatment. When it is decided to discontinue treatment,
medication is slowly tapered off Patients who are intolerant to one SSRI are switched
to another SSRI or chlomipramine. Duration and dosage of medication are optimised
in patients who partially respond to treatment.
Response to SSRIs in OCD may take longer than in many other disorders (up to
twelve weeks), thus, it is important that each patient be given a trial of medication of
adequate duration. Patients should be reassessed at the end of each trial. Cognitive
behavioural therapy is advisable prior to and during withdrawal of medication in order
to maintain gain.
Augmenting medication is administered to patients who respond poorly after optimum
trial of medication and to patients with comorbid tics. Studies demonstrate that
patients with comorbid tics show improvement of symptoms after augmentation of
SSRI with dopamine blockers (McDougle et aI., 1994). Another option, which is
becoming more common, is to supplement SSRI treatment with a low dose of
chlomipramine (Hollander et al., 1991).
When OCD does not respond to a clinical trial of optimal dose and duration, a number
of factors are taken into consideration. These include patient compliance, comorbid
substance use, comorbid personality disorders and underlying medical conditions.
These factors are assessed in unresponsive patients as they may impact on the choice
of subsequent intervention. A different agent (other than SSRIs and chlomipramine) is
used in these unresponsive patients where assessment of these factors sheds no light
on their condition.
For patients who have failed multiple medication and behavioural treatments, and in
whom the disorder is quite severe, neurosurgery is considered. Several studies have
suggested that specific lesions to the cortico-striatal pathways may lead to significant
reduction in OCD symptoms in treatment refractory patients (Jenike el aI., 1998 ).
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1.2.3.2. Cognitive behavioural therapy of anxiety disorders
The core-element of anxiety disorders such as OCD is a cognitive process in the form
of automatic thoughts or images which suddenly manifest themselves in response to a
primary stimulus, followed by intense fearfulness (Beck et al., 1994). According to
the cognitive model of anxiety disorders, it is not certain events that contribute to the
development of anxiety, but rather how these events are interpreted.
Within the cognitive model of anxiety disorders, two levels of dysfunctional thoughts
have been identified, namely negative automatic thoughts (NATs) and dysfunctional
assumptions and beliefs (Moller, 1990). Negative automatic thoughts refer to those
thoughts that are triggered spontaneously in response to a specific situation. The
contents of these thoughts involve the threat of possible physical or psychological
trauma. In most cases., these thoughts are so rapid that the patient is only aware of the
possible consequences and subsequent feelings of distress, but not of the thought
itself This makes it rather difficult for a patient to objectively evaluate the validity of
the NATs.
Dysfunctional assumptions and beliefs refer to general assumptions and beliefs which
patients have about themselves and the world around them. These beliefs make the
patient vulnerable to interpret specific situations in an unusual, dysfunctional manner
(Beck et al., 1994). These assumptions and rules form the basic structural components
of a patient's cognition and are as a result of early life events (Hawton et al., 1996).
They are the foundation that determines the patient's behaviour.
Behavioural therapy of OCD is a method whereby patients learn to perform adaptive
behaviours, instead of pathological ones in response to an intrusive thoughts or
images which comprise the core symptoms ofOCD. In order to successfully complete
therapy, patients must tolerate the uncomfortable feelings as a result of OCD
psychopathology. The term 'exposure response management' was coined in order to
describe how patients could learn cognitive strategies to cope with the intense feeling
of discomfort that arises during exposure and response prevention treatment.
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Cognitive therapy techniques
The literature describes three basic techniques of cognitive therapy for OCD:
challenging the obsessional thought, thought-stopping and challenging the negative
automatic thought.
Many techniques have been developed to challenge the obsessional thought. These
techniques typically involve either rational emotive therapy (RET) (Ellis and drysden,
1987) or self-instructional training (SIT) (Meichenbaum, 1974). Rational emotive
therapy is focused on challenging the belief in the obsessional thought through
rational disputations. Self-instructional training teaches patients to determine the level
of their anxiety, to observe and record their obsessional thoughts and replace them
with productive statements.
Thought-stopping is a process that involves interrupting the intrusive thought process
by using a cue word. Patients are instructed to use a cue word whenever an intrusive
thought presents itself. Also, patients are instructed to imagine a pleasant scene after
saying the cue word. Challenging the negative automatic thoughts is a technique that
differs from the two previously mentioned techniques in that it does not focus on the
intrusive thoughts.
1.2.4. PATHOGENESIS
Although the pathogenesis of OCD remains largely unknown, several models have
been put forward. These models include the 1) involvement of certain brain regions,
2) genetic factors and 3) immunological factors. The following section describes these
three models.
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1.2.4.1. NEUROBIOLOGICAL AETIOLOGY OF OCD
Brain regions of interest
Currently, there are several brain regions that are prime candidates as possible sites of
dysfunction in OCD.
Basil Ganglia
The basal ganglia (BG) are subcortical nuclei that compnse the extrapyramidal
system and are closely associated with the cortical and limbic structures. They consist
of the caudate nucleus, putamen and the globus pallidus (together, these three make
up the corpus striatum) and the amygdaloid complex. Historically, the BG have been
attributed a role in the modulation of corticospinal outflow or movement.
There is some evidence linking BG dysfunction with TS (Devinsky, 1983) as well as
Sydenham's chorea (Se) (Swedo et al, 1989), a disease which is closely related to
OeD. Tourette's Syndrome is a disorder that typically develops in childhood and is
characterized by tics manifested as involuntary movements or vocalizations. Just like
a compulsion, these tics tend to be exacerbated in times of stress and can be
suppressed for a short while, during which time a patient's anxiety escalates. Many
patients with TS experience concurrent symptoms of OeD. Also, there is a
disproportionately higher incidence of OCD in the family members of TS sufferers
(Lenane et ar, 1990). Similarly, Of'D patients are more likely to suffer from tics or
have family members who have tics than control individuals (Pittman, 1989).
Patients with se, which is a movement disorder that afflicts up to 20% of patients
suffering from rheumatic fever (RF), have a higher prevalence of OCD symptoms
than individuals with RF without se (Swedo el al, 1989).
The BG are implicated in OCD beyond the above mentioned mutual relationship
between movement disorders. The BG nuclei participate in cognitive aspects of
behaviour, whereas the motor functions of the BG are carried out predominantly by
the putamen, the cognitive functions are thought to be carried out by the caudate
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nucleus (Cote et al, 1995) (fig 3a). Thus, the BG are involved in thought, and
abnormalities in these structures could result in obsessions and repetitive patterns of
behaviour.
Computerized tomography has suggested structural differences in the brains of OCD
patients and control individuals. Ventricular/brain ratios have been shown to be
enlarged in OCD patients (Behar, el al, 1984) and caudate volumes were found to be
reduced in OCD patients as compared to normal control individuals (Luxenberg, et
al, 1988).
Positron emission tomography (PET) studies have revealed increased metabolic
activity of the caudate bilaterally in the brains of OCD patients compared to control
individuals (Baxter et al, 1987) and in two separate case reports, OCD patients were
found to have local lesions involving the caudate and putamen as determined by MRl
(Wei Iburg et al, 1989; Williams et al, 1988).
Frontal Cortex
The frontal lobes are associated with neuropsychological functions of programming,
regulating, controlling and verifying behaviour. Therefore, frontal lobe pathology
correlates with inflexibility, decreased response inhibition, preservation and
stereotypy, characteristics which are reminiscent of OCD symptoms (Otto, 1990).
Frontal lobe dysfunction has been implicated in some neuropsychological studies of
OCD (Flor-Henry et al, 1985; Behar el al., 1984; Malloy et al., 1989). For example,
PET studies have consistently shown increased frontal cortical metabolism in OCD
patients compared to control individuals (fig 3b). Positron emission tomography
analysis of ten OCD subjects and ten controls demonstrated increased metabolism in
the orbital gyrus and orbital gyrus/ipsilateral hemispheric ratio bilaterally in the
patient group (Baxter, 1992). These findings have been replicated (Nordahl et al.,
]989) Similarly, PET investigation of 18 adult childhood-onset OCD subjects, versus
control individuals, revealed increased metabolism of the bilateral prefrontal areas
and an increase in left orbitofrontal cortex (Swedo et al., 1989).
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Limbic Structures
The limbic system consists of several interconnected structures that are believed to
serve as the neural substrate for drive-related and emotional behaviour. Limbic
structures include the septal area, hippocampus, cingulum, amygdala and certain
portions of the temporal lobe (particularly the parahippocampus gyrus).
Animal models of OCD include bilateral hippocampectomised rats that display
repetitive behaviours, invariability, enhanced avoidance and excessive behaviour
(Pitman, 1989). One model provides data suggesting that the septohippocampus
interacts with cortical outputs to compare sensory information with anticipated
conditions. It then modulates behaviour accordingly. This 'comparative' pathway
responds to novel or threatening stimuli with behavioural inhibition, enhanced
attention and arousal. So the repetitive behaviour seen in OCD may be due to a
malfunction in the septohippocampus.
The cingulum is closely related to the septohippocampal system and the
thalamocortical tracts. Positron emission tomography analysis of OCD subjects has
shown increased metabolic activity bilaterally in anterior cingulated cortex (Swedo et
ar, 1989). Also, it has been shown that cingulated lesions ameliorate OCD symptoms
in some patients (Martuza et al., 1990; Jenike et al., 1991; Kelly et ar, 1973) and may
act by disrupting the thalamocortical tract, as seen in leucotomy (Rees, 1973). It has,
therefore, been proposed that cingulum hyperactivity may playa role in compulsive
behaviour.
The temporal lobes were initially thought to be involved in OCD because of the
clinical similarities between OCD and temporal lobe epilepsy. Complex partial
seizures are characterised behavioural manifestations which include "forced thinking"
that is practically indistinguishable from obsessions experienced in OCD (Bear,
1985) In addition to this, several reports have demonstrated that temporal lobe
electroencephalogram (EEG) abnormalities coincide with OCD (Jenike, 1984). There
are, however, studies that found no significant EEG abnormalities in OCD patients
compared to control individuals.
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Fig 3: Drain regions involved in OeD pathogenesis. 3A: The structure of the basal
ganglion showing the caudate nucleus, which is responsible for cognitive functions,
the globus pallidus and the putamen, which is responsible for motor function (taken
from www.ncbi.nih.gov/publicat/ocdbrain.htm). 3D: PET scan of a control
individual's brain (left) and an OCD patient's brain (right). These scans show an
increased frontal cortical metabolism in OCD patient compared to the control
individual (taken from www.ncbi.nih.gov/publicatlocdbrain.htm).
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In summary, by using a variety of brain scanning techniques, researchers have shown
anatomical and metabolic variations in various brain regions (BG; frontal cortex and
limbic structures) of OCD patients compared to control individuals, thereby
implicating these regions in OCD pathogenesis.
1.2.4.2. GENETIC AETIOLOGY OF OCD
The genetic model of OCD is largely based on the pathways of neurotransmission and
neurotransmitter metabolism (fig 4). These pathways are regulated by a host of
enzymes and receptors, functional variants of which many may be considered good
candidates for increased susceptibility to OCD. The following section will deal with
the components of the neurotransmitter metabolic pathways and, specifically, the
enzymes involved in these pathways, as well as the 5-HTT, which facilitate
neurotransmission. For the purpose of this thesis, the catechol-O-methyltransferase
(COMT) and the serotonin transporter (SLC6A4) genes will be discussed in detail,
while other possible candidates genes whose products are involved in these pathways
will be mentioned briefly. Firstly, however, family studies of OCD will be discussed,
since they provide some evidence for the genetic aetiology ofOCD.
1.2.4.2.1. Family studies of OeD
Although the aetiology of OCD remains largely unknown, several investigations in
the past have indicated that OCD is familial. Several twin studies have found that
concordance for OCD is substantially greater in monozygotic twins (53%-87%) than
dizygotic twins (22%-47%) (Rasmussen and Tsuang, 1986). These findings have
provided limited evidence for the importance of genetic factors, and, although a
number of family studies on OCD have been completed, the subject remains
controversial.
Some studies found rates of OCD as high as 35% (Lenane et aI., 1990) among first-
degree relatives of OCD probands, whereas other studies found no increase in rates
(Rosenberg 1967; Insel et al., 1983). There are many reasons for these discordant
results, such as differences in diagnostic criteria and methods of assessment. Most of
the earlier studies did not directly interview relatives ofOCD sufferers, while others
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Fig 4: Schematic representation of the synthesis and degradation pathways of
neurotransmitters. Enzymes shown in red are those enzymes used in the present
association study, while those shown inpurple are the subject of a concurrent study.
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failed to include control groups. During the early 1990's, five studies addressed the
shortcomings of the earlier studies (Lenane el al., 1990; Riddle et al., 1990, Bellodi et
al., 1992; Black et al., 1992; Leonard et al, 1992). Findings from these studies
provided further support for the hypothesis that there is a familial component in some
forms of OCD. More recently, two further family studies of OCD have emerged
(Pauls et aI., 1995; Nestadt el al., 2000), both of which provide further evidence for
the familial nature of OCD and which have lead the authors to speculate on the
presence of a gene of major effect which contributes to the pathogenesis of OCD.
While these findings are consistent with a genetic aetiology of OCD, familial studies
by themselves are not able to determine whether genetic factors playa major role in
the manifestation of OCD. Data generated from such family studies are used to
examine specific genetic hypotheses using segregation analysis. If segregation
analysis reveals that patterns within families are consistent with a fairly simple mode
of inheritance, the results can then be taken as further evidence for the importance of
genetic factors in OCD pathogenesis The mode of inheritance of OCD has been
investigated by means of segregation analysis in four independent studies (Nicolini et
al., 1990, 1993; Cavallini et al., 2000; Nestadt et ar, 2000). Two of these studies
(Nicolini et aI., 1991; Cavallini et al., 2000) suggested a gene of major effect, but
failed to show any distinct mode of inheritance. The study by Nestadt et al., (2000),
investigating 80 case families and 73 control families, showed strong evidence
supporting a mendel ian dominant or codominant mode of inheritance.
Additional support for the involvement of specific genes in OCD comes from twin
and family studies of TS, which have shown a high rate of OCD among TS families
(Pauls el aI., 1986). As the latter familial condition appears to have a substantial
genetic basis (Pauls, 1992, Simonie et al., 1998), the higher rate of OCD among the
relatives of TS probands suggests that certain forms of OCD might be genetically
related to TS.
In summary, in the studies discussed above, the genetic basis of OCD remains a
contentious issue and, although family and twin studies provided some evidence for
genetic factors involved in OCD, conclusive evidence is still lacking.
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1.2.4.2.2 The Serotonin Hypothesis
The 5-HT system is consistently implicated in the development of OCD and the most
consistent pathophysiological finding in OCD points toward abnormalities in 5-HT
neurotransmission. Neurotransmission mediated by 5-HT contributes to many
physiological functions such as motor activity, food intake, sleep and reproductive
activity. It also contributes to cognition and emotional states including mood and
anxiety (Ramboz et al., 1998).
The efficacy of SSRls, and the absence of improvement of OCD symptoms after
treatment with norepinepherine reuptake inhibitors and dopamine antagonists,
presents strong evidence for the involvement of 5-HT in the pathophysiology of OCD
(Barr et al., 1992; Goodman et al., 1990; Murphy et al., 1989).
Taking into account that 5-HT neurotransmission could playa major role in the
pathogenesis of OCD, genes in the serotoneric pathway, such as the 5-HT transporter
(SLC6A4) and serotonin receptors (5-HIR), are good candidate genes for conferring
susceptibility to OCD.
1.2.4.2.3. Catecholamine metabolism
Several studies have implicated catecholamine metabolism (fig 4) in psychiatric
disorders and, more specifically, anxiety disorders (Mallet et al., 1994). This
metabolic pathway harbours several key enzymes and many genes encoding these
enzymes, eg., COMT and monoamine oxidase A (MAO-A), are considered plausible
candidate genes for increased susceptibility to OCD.
1.2.4.2.4. Candidate Genes
Catechol-O-methyltransferase (COMT)
Catechol-O-methyltansferase is a physiologically important enzyme that catalyses the
transfer of the methyl group from S-adenosyl-L-methionine to a phenolic hydroxyl
group of catechol neurotransmitters, catechol steroids and catechol drugs (fig 5)
(Axelrod, 1966; Campbell et al., 1984). The gene encoding COMT has been localised
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to chromosome 22q 11.I-q 11.2 by Grossman et al., (1985). In the brain, COMT
degrades catechol amines such as norephinepherine, epinephrine and dopamine (Fig
5) into O-methyl esters (Guldberd and Marsden, 1975).
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Fig 5. Methyl transfer from S-adenosyl-L-methionine to catechol in a COMT
catalysed reaction
Cell fractionation and immunological studies have shown that the COMT enzyme
occurs as two distinct forms in mammals: in the cytoplasm as a soluble form (S-
COMT) and associated with membranes as a membrane-bound form (MB-COMT)
(Assicot and Bohuon, 1971). S-COMT activity is the more prevalent form in all
tissues, while MB-COMT generally represents less than 5% of the total COMT
activity (Guldberg and Marsden, 1975; Jeffery and Roth, 1984; Grossman et aI.,
1985). However, in the brain, MB-COMT activity has been reported to be higher than
in other tissues (Rivett et al., 1982).
Rat and human S-COMT and MB-COMT cDNAs have been cloned and characterised
(Bertocci et al., 1991; Lundstrom et al., 1992; Tilgmann et al., 1992) (fig 6). Both S-
COMT and MB-COMT are encoded by one gene, but are transcribed using two
distinct separate promoters (Tenhunen et al., 1994). The S-COMT promoter contains a
633 base pair (bp) open reading frame (ORF) encoding the S-COMT protein
(Lundstrom el aI., 1992; Salminen et aI., 1990). The translation initiation codon for
the MB-COMT form in humans is located 150 bp upstream from the S-COMT form in
the same ORF. According to these results, the S-COMT (25 kDa) and the MB-COMT
(30kDa) polypeptides are partly identical, but with MB-COMT containing an amino
(N)-terminal extension that carries a stretch of hydrophobic amino acids which is not
present in the S-COMT sequence. This hydrophobic N-terminal end of MB-COMT is
responsible for cotranslationally directing the MB-COMT protein to the membrane by
acting as a signal-anchor domain (Ulman and Lundstrom, 1991).
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The COMT gene is of interest in the pathogenesis of OCD for three reasons:
Firstly, the argumentation of SSRI treatment with dopamine agonists appears to be
useful in a subset of OCD patients (McDougle et al., 1994) implicating the
involvement of dopaminergic pathways in OCD pathogenesis.
Secondly, it has been previously reported that patients with 22q 11 microdeletions
manifest a number of psychiatric phenotypes (Bassett et al., 1999; Karayiorgou et al.,
1995; Pulver et al., 1994). Deletions in this region are responsible for chromosome 22
deletion syndrome (22qDS), the second most common genetic syndrome that affects
approximately one in 4000 individuals world-wide (du Montcel el al., 1996). The
syndrome encompasses velocardiofacial syndrome (YFCS), DiGeorge syndrome and
conotruncal anomaly face syndrome (CT AFS), all due to chromosome 22q 11.2
microdeletions (Demczak and Aurius et al., 1995), which generally occur de novo
(Deczak and Aurius et al, 1995; Leana-Cox et al., 1994). Learning disabilities, palatal
anomalies, cardiac defects and atypical facial features are common, although the
presentation is highly variable (Yamagisgi et al., 1998). It is inferred that the
symptoms associated with the deletions, which vary in extent in different patients, are
associated with the loss of particular genes harboured in the missing region. Most
interestingly, a review of 22qDS found that psychiatric disorders, of which
schizophrenia was the most frequent, were reported in 53% of cases of 22qDS that
were not ascertained from psychiatric sources (Papalos et al., 1996; Pulver et al.,
1994) and that another group of patients showed obsessive-compulsive symptoms
(Karayiorgou et al., 1997) A follow-up study (Papoios et al., 1996) in patients with
22q 11 deletions reported OC symptoms in a majority of these patients. These findings
provide strong evidence that genes involved in increased OCD susceptibility may be
harboured at the 22q Il region. The gene encoding COMT maps to this region and is
frequently deleted in patients with 22qDS and has also been linked to schizophrenia
susceptibility in various studies (Liou et al., 2001; de Chadlee et al., 1999; Lachman
et al., 1998).
Thirdly, a functional polymorphism in COM?; in which the high (H) and low (r)
activity alleles encode a valine or methionine amino acid residue, respectively, at
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Fig 6. A: Exon-intron organization of the human COMT gene. The COMT gene
consists of 6 exons indicated by open and blue rectangles. Solid blue rectangles
represent transcribed regions, whereas open rectangles represent untranslated regions.
Intron sizes are indicated in red font, while exon sizes are indicated in blue font. The
gene codes for two distinct forms of the enzyme (MB-COMT and S-COMT) and each
form is transcribed from a distinct promoter indicated by dashed lines. The red arrow
shows the relative position of ERE6. The MB-COMT start codon is located at position
+1while the S-COMT start codon is located at position +151. The stop codon for both
forms is located at position +814. The NIaIlI polymorphism is located in exon 4 as
shown by the black arrow (adapted from Lotta et al., 1995)
B: mRNA species for both S-COMT and MB-COMT. (Adapted from Lotta et al,
1995). S UAG represents the start codon for the soluble form of COMT, while MB
AUG represents the membrane-bound form start codon.
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position 158 of the protein, has been described. There is a three- to four-fold reduction
in enzyme activity between the variants encoded by the H/H and DL genotypes, with
heterozygotes (HL) showing intermediate enzyme activity. This polymorphism is
represented by a G to A transition resulting in the creation of an NlaIII restriction
enzyme site (Lachman el aI., 1996) and was used in two North American studies to
determine the role of COMT in OeD. Both of these studies showed an association
between OeD and the L allele of COMT (Karayiorgou et al., 1997; Karayiorgou et
al., 1999).
Furthermore, there is evidence that oestrogen downregulates COMT transcription.
Therefore, high levels of oestrogen may directly lower its expression (Xie et al., 999).
Several half-palindromic oestrogen response elements (EREs) have been identified
within the promoter regions of COMT (Xie et al., 1999), of which ERr_'6 was found to
have a major influence on the oestrogen-dependant regulation of CGMT.
Many genes containing EREs have been identified, with many of them containing one
or more polymorphism within a 13 nucleotide consensus sequence (Driscoll et al.,
1998). Although there is no published data which suggests that E'RE6 is polymorphic,
it is possible that a polymorphism in this element could have an effect on COMT
transcription and expression levels and thus be implicated in OeD pathogenesis.
Serotonin Transporter (5-HTT)
Serotonergic neurotransmission is terminated by the active transport of 5-HT back
into the presynaptic neuron by the serotonin transporter protein (5-HTT). The latter
regulates the magnitude and duration of serotonergic responses by mediating the
sodium-dependant re-uptake of 5-HT into presynaptic nerves, and, in so doing, it is
central to the fine-tuning of brain serotonergic neurotransmission and peripheral
actions of 5-HT (Lesch el al., 1996). The serotonin transporter protein expression in
the brain is notably abundant in the cortical and limbic areas involved in the
emotional aspects of behaviour. It is also expressed in blood and expression levels are
similar to that found in the brain (Greenberg et al., 1999)
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Fig 8. The serotonin transporter gene (SLC6A4). A: Organization of the human 5-
HTT gene and its flanking regulatory region on chromosome 17qll.2. Solid rectangles/
open rectangles represent coding regions. The bold horizontal line represent intronic
sequence. B: The 5-HTT 5' flanking region. The 5-HTT promoter is defined by a
TATA-like motif, and several potential binding sites for transcription factors, including
API, AP2 and SPI, are present in the 5' flanking region. The position of the 5-H1TLPR
is indicated by the purple rectangle. C: The 5-H1TLPR showing the presence of the
44bp deletion (short allele) and the presence of the 44bp insertion (long allele). Adapted
from Heils et al., 1996.
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The 5-HTT protein is one of several structurally similar sodium-dependant transporter
proteins that contain 12 putative membrane-spanning regions (Amara and Kahar,
1993) (fig 7). The human 5-HTT is encoded by a single gene on chromosome 17q12,
which is organised into 14 exons spanning approximately 35 kilobases (kb).
(Ramamoorthy et aI., 1993) and has the official gene symbol SCL6A-I (solute carrier
family 6 [neurotransmitter serotonin], member 4). A unique Ge-rich repetitive
sequence is located in the proximal 5' regulatory region of SCL6A4. Heils et al.,
(1996) revealed a common polymorphism in this region (5-HTTLPR) generated by a
44bp insertion! deletion sequence (l/s) (Fig 8).
SCL6A4 is of interest for its involvement in OeD for a number of reasons. Firstly,
there is a substantial body of work that implicates the 5-HT system in the
development of OeD, including the finding that OeD responds selectively to 5-HT
reuptake inhibitors (Murray et aI., 1996). Secondly, the 5-HTTLP (1/5) polymorphism
in SCL6A4 has been shown to have a significant effect on blood 5-HT content (Hanna
et al., 1998 Lesch et al., 1996).
In an association study between .s'CL6A-I and OeD, McDougle et aI., (1998)
employed a TDT design (section 1.1.2.3.) in 34 European-American triads and found
that the I allele of 5-HTTLPR was significantly more commonly transmitted by
heterozygous parents to their OeD affected offspring. In a population-based
association study, Bengel et al., (1999) demonstrated that OeD patients were more
likely to be homozygous for the 5-HTTLPR I allele than control individuals. Another
study, however, found that the 5-HTTLPR polymorphism did not appear to influence
response to pharmacotherapy in OeD, thus raising some doubt about the functional
importance of the above-mentioned findings (Billet et aI., 1997). Similarly, early
reports of an association between SCL6A4 alleles and anxious and depressive traits
(Lesch et aI., 1996) have not been replicated (Gelernter et aI., 1998).
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Fig 7. The structure of rat 5-HTT. The rat 5HIT has been studied extensively. This
schematic representation of rat 5HIT shows homologous amino acids with the rat
dopamine transporter (DAT) and human norepinepherine transporter (NET). P
indicates possible phosphorylation sites while the blue arrow shows possible
glycosylation sites (Adapted from Frazer et al., 1999).
Monoamine Oxidase A (MAO-A)
Monoamine oxidase (MAO) is a flavin containing enzyme that degrades a variety of
biogenic amines, including the neurotransmitters norepinepherine, dopamine and 5-
HT (Weyler et al., 1994) (fig 4). Two forms of the enzyme, MAO-A and MAO-B,
have been identified on the basis of the difference in their molecular weight, substrate
specificity, substrate affmities, inhibitor sensitivities and immunological properties
(Garrick and Murphy, 1982). In the human brain, MAO-B is the prominent form
(Garrick and Murphy, 1982) expressed at the highest levels in the astrocytes and
serotonergic neurons. In contrast, MAO-A is expressed at highest levels in the
catecholaminergic neurons (Fowler et al., 1987;Thorpe et al., 1987).
Variations in MAO activity appear to affect neurophysiological and behavioural traits
in humans and in animals. In MAOA knock-out mice, 5-HT levels in the brain have
been shown to be increased up to nine-fold, with the mice exhibiting distinct
behavioural changes (Cases et al., 1998).
In humans, moderate inhibition of MAOA and MAOB activity can lead to mood
elevation, loss of 'rapid eye movement' (REM) sleep, motoric hyperactivity,
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orthosomatic hypertension and hyperflexia without spasticity (Kupfer and Bowers
1972; Murphy et al., 1983; Squires et al., 1978).
The two protein-encoding genes, MAO-A and MAO-B, have been mapped to the
p 11.23-11.4 region of the X chromosome (Ozelius et al., 1988; Levy et al., 1989).
They each comprise 15 exons with identical intron-exon organisation but encode
proteins with different polypeptide compositions. Brunner et al., (1993) studied a
Dutch family, with five male cases of X-linked borderline mental retardation and
behavioural disturbances, screening for MAO gene mutations and assaying MAO-A
activity levels. A point mutation was detected in exon 8 of MAOA, resulting in a
truncated and non-functional MAOA protein. All of the affected males exhibited
abnormal and often overly aggressive behaviour including arson, rape of a female
relation, exhibitionism, voyeurism and one, after being criticised, attempted to murder
his supervisor. This study offers a correlation between inappropriate emotional
responses and the elimination of MAO A activity via a genetic mutation.
1.4.2.4.5 Other candidate OCD susceptibility genes
As the candidate genes discussed below do not form part of the present study, but
rather of a concurrent study, they will be discussed briefly.
Tryptophan hydroxylase
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the synthesis of 5-HT
(fig 4). Abnormalities in 5-hydroxyindoleacetic acid (5-HIAA) concentrations, the
major metabolite of serotonin in the brain and cerebrospinal fluid, have been
described in depression, schizophrenia and impulsive aggression (Tuckwell and
Kozoil, 1996). Tryptophan hydroxylase may be an important contributor to treatment
response, given the fact that SSRI's depend on the availability of serotonin to exert
their effect via transport inhibition. Therefore, this enzyme is an ideal candidate for
OCD susceptibility.
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Tyrosine hydroxylase
Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the synthesis of
catecholamines (fig 4). A deficiency of TH leads to decreased cerebrospinal fluid
levels (CSF) of homovanillic acid and 3-methoxy-4-hydroxyphenylethyleneglycol,
together with normal CSF tyrosine and S-hydroxy-indole-acetic acid concentrations
(Wevers et al 1999). Functional polymorphisms of the JH gene may therefore be
involved in the pathogenesis of both manic depressive episodes, panic disorder and
OCD .
Serotonin Receptors
Since many studies indicate that abnormalities in the serotonergic system playa major
role in the development of OCD, the 5-HT receptor genes are very attractive
candidate genes. The 5-HT receptor family is divided into seven main branches that
each contain 1- 4 individual receptor genes (Peroutka, 1994). All 5-HT receptors are
coupled to G-proteins linked to an adenyl cyclase or to the phospho-inositol system,
except 5-HT receptor 3 (5-HT3) which is an ion channel. Many 5-HT receptor genes
have been implicated in a variety of psychiatric disorders and personality traits. The
5-HT receptor 2C (5-HT2c) gene (5-HTR2C) has been associated with the personality
trait of reward dependence (Ebstein et aI., 1997), while 5-HT2a receptor densities
have been shown to be decreased in patients with neuroleptic-naïve schizophrenia
(Ngan et al., 2000). Also, a 5-HT2a receptor polymorphism has been implicated in the
development of bipolar affective disorder (Massat et al., 2000).
1.2.4.3 IMMUNOLOGICAL AETIOLOGY OF OCD
Immune-based theories of OCD pathogenesis stem from the observed similarities
between its symptoms and those ofSC. Sydenham's Chorea is a disorder developed in
a subset of patients with RF, and is thought to be an immunological illness in which
infection with group A B-haemolytic streptococci (GABHS) induces the production of
antibodies that cross-react with neuronal proteins (Taranta et al., 1956).
Swedo et al., (1989) showed that patients with SC might show OC symptoms in up to
75% and OCD in 33% of cases. Furthermore, a symptom pattern of sudden dramatic
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onset and slow waxing and waning over a period can be found in SC and a subgroup
of OeD (Leonard, 1993; Swedo el al., 1989; Swedo et al., 1994). This symptom
pattern was described in four paediatric patients by Allen el al., 1995. These
observations provided a diagnostic criterion for a subgroup of patients called
paediatric, infection-triggered, autoimmune neuropsychiatric disorders (PITANDs)
(Allen el al., 1995). Subsequently, many cases of paediatric autoimmune
neuropsychiatric disorders associated with streptococcal infection have been
described (PANDAS) (Swedo et al., 1997) The diagnostic criteria of PANDAS
include evidence of adventitious movements (eg., mild chorea of motor hyperactivity)
(Swedo et al., 1998). The presence of abnormal movements (eg., choreiform) has
been reported in OeD patients (Hollander el al., 1989), while tic-like movements
have been reported in streptococcal infection and sc (Kiessling et al., 1993).
The involvement of the BG in both Oï.D and SC has been well documented (Berthier
et al., 1996, Giedd et al., 1995; Hebebrand et al., 1993; Heye et al., 1993). In a recent
study, BG enlargements were found among patients with PANDAS (Giedd et al.,
2000). This result was found to be similar to a report of BG enlargements in patients
with SC (Giedd el al., 1995) Taken together, these studies are consistent with the
hypothesis of cross-reactive antibody-mediated inflammation of post-streptococcal
OeD or tics in some patients. These studies, however, did not demonstrate a
relationship between BG size and symptom severity, which may indicate that BG size
and pathophysiology are not directly related.
08/17 is a monoclonal IgM antibody that was isolated by Khanna et al., (1989). This
84 kOa antibody is B-cell specific and has not been detected on T-cells or
macrophages. Kemeny et al., (1994) showed that D8/17 recognises a helical-coiled-
coil structure on the surface of B-cells that is similar to molecules such as myosin,
tropomyosin and the M6 protein of group A streptococci. It cross-reacts with
triophosphate isomerase and binding of 08/]7 to frozen heart sections can be
absorbed by antigens isolated from some strains of group A streptococci, but not by
others.
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The non-Hl.A B cell surface antigen, recognised by D8/17, was found to be expressed
at higher levels in patients with RF compared to controls (Khanna et al., 1989). Since
this marker was not found at elevated levels in post-streptococcal glomerulonephritis
or other autoimmune disorders, it may indicate that D8/17 might be an indicator of
vulnerability to specific complications of RF, like SC (Gibofsky et aI., 1991) Follow-
up studies, using a rapid testing procedure, found that patients with a history of RF
showed elevated D8/17 levels although they had no active RF at the time of testing
(Herdy et al., 1992).
Among psychiatric disorders, childhood-onset OCD and TS were associated with
higher expression of D8/17 than control subjects (Chapman et al., 1998; Murphy et
al., 1997; Swedo et al., 1997). Niehaus et al., (1999) also reported a significant group
difference in the mean expression of D8/17 in a small sample of OCD patients,
trichotillomania (TTM) patients and controls (Niehaus et al., 1999). This study
showed that South African patients with OCD had significantly higher average
percentage of B-cells expressing D8/17; however, because of the relatively small
sample size, and high mean percentage ofB cells expressing D8/17 in the TTM group
and control individuals, a follow up study was needed. The follow-up study forms
part of this thesis.
1.2.5. THE PRESENT STUDY
The pathogenesis of OCD still remains largely unknown, with many theories and
models being proposed. The present study investigated two proposed mechanisms of
OCD pathogenesis, broadly classified as the genetic and the immunological
aetiologies of the disease.
The strategy used in the genetic approach, which investigated the role of two
candidate genes, namely COMT and SLC6A -I in the pathogenesis of OCD, was a
population-based case-control association study. Previously described polymorphisms
implicated in the development of OCD, ie, the COMtlNlalII and the SJJ'6A-I/5-
HTlJ_PR polymorphisms, were used in a comparison of the genotype distribution and
allele frequencies between a group of unrelated OCD affected individuals and a group
of unrelated control individuals and thus assess the role of these genes in OCD
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pathogenesis. In order to reduce genetic complexity, this study was conducted in the
homogeneous Afrikaner sub-population of South Africa.
The COM'DNlaIII polymorphism was genotyped USIng allele specific restriction
enzyme analysis, (ASREA), while the SLC6A4/5-H777_PR polymorphism was
genotyped using polymerase chain reaction (PCR) and direct assessment of the size of
the amplified products.
A recent report showing that the promoter regions of COMT contain several EREs
prompted a search for possible polymorphisms within EJU,-'6,which has been shown
to be important in oestrogen-dependant regulation of COMT, in the present study.
PCR-single stranded conformational polymorphism (PCR-SSCP) was the method of
choice used to determine whether ERE6 was polymorphic. Upon the detection of a
mobility shift within the amplified PCR fragments containing ERE6, the fragments
were sequenced to identify the variation. The sequence variation thus identified was
then genotyped in the study population to determine whether it was associated with
OCD.
Furthermore, the role of an immunological marker, 08/17, in OCD was investigated,
as previous studies have shown that 08/17 may be a useful trait marker for early onset
OCD (Swedo et al., 1997; Murphy et al., 1997) Thus this study aimed to determine
whether this marker could possibly be used as a trait marker for late-onset OCD and
to evaluate its specificity within the spectrum of anxiety disorders.
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CHAPTER2 MATERIALS AND METHODS
PART I: GENETIC STUDY
2.1 STUDY SUBJECTS
All patients and control subjects participating in this study were of Afrikaner descent
based on Afrikaans being their home language and at least three of their four
grandparents being of Afrikaner descent.
Unrelated OCD patients and controls were recruited through the Medical Research
Council (MRC) Unit on Anxiety and Stress Disorders from throughout South Africa
by trained clinical psychologists and via media advertisements. These controls were
matched to the case subjects according to ethnicity, gender and age. The University of
Stellenbosch Ethics Committee approved the protocol and all subjects provided
written informed consent.
All patients underwent a structured interview, which included the SCID-I, the Yale-
Brown Obsessive-Compulsive Scale (Y-BOCS) and the Yale Global Tic Severity
Scale (YGTSS) (First et al., 1994; Goodman et al., 1989; Leekman et al., 1989), and
which was conducted by a trained research clinician.
All patients met DSM-IV criteria for OCD and had no history of psychotic disorder.
Controls underwent a semi-structured interview (SCID-I screening). Control
individuals included in the genetic study had no reported history of an anxiety, mood
or psychotic disorder. The control group used in the immunological study was divided
into three groups namely, an anxiety disorder group, in which subjects met DSM-IV
criteria for either SP or PO, a OC spectrum disorder group, in which subjects met
DSM-IV criteria for TTM, and a healthy control group, in which subjects had no
reported history of any anxiety or mood disorder. All subjects included in the
immunological study also had no history of RF or Sc.
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2.2 BLOOD COLLECTION
Blood samples were drawn from both patients and control individuals by means of
venous puncture and collected into 5 ml etheylene-diamine-tetra-acetic acid (EDT A)
tubes. The EDT A tubes were collected immediately if blood was drawn at the MRC
Unit on Anxiety and Stress Disorders, while blood from patients from around South
Africa was couriered to the research laboratory within 24 hours of sampling.
2.3 DNA EXTRACTION
±.3.1. Extracting nuclei from whole blood
Blood from three Sml EDTA tubes per patient was transferred into a SOml Falcon
tube. The tube was then filled to 20 ml with ice-cold lysis buffer (appendix I). After
gently inverting the tubes a few times, the sample was incubated on ice for 5-10
minutes. The sample was then centrifuged at 2500-3000 rpm at room temperature in a
Beckman model TJ-6 centrifuge (Scotland, UK). The supernatant was discarded and
the pellet was resuspended in 20ml, ice-cold lysis buffer, followed by another round
of incubation and centrifugation. The supernatant was then discarded and the pellet
resuspended in 900~1 sodium-EDT A (appendix I) and 100~1 10% sodium dodecyl
sulphate (SDS) (appendix I). The nuclei were then either immediately used for DNA
extraction or stored at -70°C until DNA was required.
2.3.2. Extracting DNA from nuclei.
To the freshly prepared or thawed nuclei, 100~1 of proteinase K (1Oug/ml) was added
and the mixture was incubated overnight at 37°C. After this step, 2ml distilled water,
SOO~13M sodium-acetate (appendix I) and 2S~1 phenol/chloroform (appendix I) were
added to the sample. The tubes were subsequently inverted and mixed gently for 10
minutes on a Voss rotator (Voss of Maldon, England) at 4°C. The mixture was then
transferred to a glass Corex tube so that the aqueous phase could be clearly
distinguished from the organic phase, followed by centrifugation in a Sorvall RC-SB
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refrigerated super-speed centrifuge (rotor SS 34, Dupont Instruments) at 8000 rpm for
10 minutes at 4°C.
The upper aqueous phase containing the DNA, was transferred to a clean Corex tube
using a sterile plastic pasteur pipette, while taking care not to disturb the interface or
the organic phase. Approximately 25ml chloroform/octanol (appendix I) was added to
the aqueous phase after which the tube was closed with a polypropylene stopper and
gently inverted for 10 minutes. This mixture was then centrifuged at 4°C, followed by
the removal of the upper aqueous phase as described earlier. The DNA was then
ethanol precipitated by adding two volumes of ice-cold 96% ethanol and inverting
gently until DNA strands appeared as a white precipitate.
The DNA strands were removed using a yellow tipped Gilson pipette and placed in a
clean, 1.5ml Eppendorf microfuge tube. One millilitre 70% ethanol was then added to
the DNA and the mixture centrifuged in a Beckman microfuge for 3 minutes at 13000
rpm. The ethanol was carefully decanted and the 70% ethanol wash repeated one
more time in order to remove any excess salts. After careful removal of most of the
ethanol, the DNA pellet was air-dried for 30-60 minutes at room temperature by
inverting the Eppendorf microfuge tube on Carlton paper. Two hundred microlitres
Tris-EDTA (appendix I) buffer was added and the DNA was resuspended initially by
stationary incubation at 37°C overnight and subsequently by gentle mixing in a Voss
rotator (Voss of Maldon, England) at 4°C for a further 3 days. This was followed by
stationary incubation at 4°C until the DNA has been resuspended.
After 1-3 weeks, when the DNA had completely resuspended in the buffer, the optical
density (00) of the DNA was determined in a Milton Roy series 120i
spectrophotometer (USA) at 260nm (00260). The DNA concentration was determined
by diluting IOlll of DNA in 500lli of TE and multiplying the measured 00260 by a
factor of2.5. This gave the DNA concentration in llg/ ul. The purity of the DNA was
determined by calculating the ratio of the 00260 and the 00280, which should be
approximately 1.8 for pure DNA.
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2.4. POLYMERASE CHAIN REACTION (PCR)
Polymerase chain reaction (PCR) is a technique which provides a rapid means of
exponentially amplifying a specific target region of DNA flanked by unique regions
to which oligonucleotide primers are designed (Saiki et al., 1985) (fig 9). The PCR
technique was used to amplify the NlaIII polymorphic (Karayiorgou et al,1997)
region and the region containing ERE6 of COMT (Xie et aI., 1999), as well as 5-
HTILPR of SCL6A4 (Gelernter el al., 1997).
2.4.1. Oligonucleotide primers
Oligonucleotide primers are important in the PCR reaction as they are homologous to
the unique sequence flanking the area being amplified, which makes PCR very
specific. The DNA polymerase finds where these primers bind to the single stranded
DNA before forming a new double strand in the 5'-3' direction during amplification
of the area of interest (fig 9). Oligonucleotide primers were synthesised according to
standard phosphoramidite methodology at the Department of Biochemistry,
University of Cape Town (UCT), Cape Town, South Africa. Primers for the
COMTINlaIII (Karayiorgou et al., 1997) polymorphism and 5-HTIIPR (Gelernter et
al., 1997) were synthesised according to published sequence, while oligonucleotide
primers for COMT/ERE6 were designed from published COMT promoter sequence
using the DNAMAN (Lynnon Biosoft Copyright'" computer programme. The primer
sequences for each polymorphic site genotyped are shown in table 1.
2.4.2. peR conditions
DNA amplification was performed in a 50111reaction containing O.lllg genomic DNA
as template, 75jlM of each of dATP, dCTP, dGTP and dTTP (Promega Corp,
Madison Wisconsin USA), 5111of a lOx Taq DNA polymerase butTer (Bioline UK
Ltd, London, UK), 150ng of each oligonucleotide primer (Table 1), 0.5U Taq DNA
polymerase (Bioline UK Ltd, London, UK), 5% glycerol (Sigma chemical company,
St Louis, Missouri, USA) and water to a final volume of 50111.Mineral oil was added
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separated complementary DNA strands
3' 5'
defined
primers
3'5'
3' 5'
5' 3'
X nucleotide pairs
Fig 9a. Amplification of specific nucleotide sequences in vitro using peR. DNA isolated
from cells is heated to 94°C in order to separate its complementary strands. Oligonucleotide
primers (one complementary to each strand) that have been chemically synthesized according
to known sequence flanking the region to be amplified, are then annealed to the single
stranded DNA by lowering the temperature from 94°C to a previously determined annealing
temperature. The two oligonucleotide primers designed are specific to the target region to be
amplified. A DNA polymerase fmds the binding site of the primers to the DNA strand, and
creates a new double strand using nucleotide bases in the PCR reaction mixture. The newly
synthesized strands are complementary to the original separated DNA strands, thus creating
two new double-stranded DNA molecules. This cycle is repeated 30 times and the amount of
DNA produced by this reaction doubles in each cycle. Adapted from Molecular Biology of
the Cell, 3rd edition.
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Fig 9b. peR amplification. PCR produces an amount of DNA that doubles in each cycle of
DNA synthesis and includes a uniquely sized DNA species. After numerous cycles of
reaction, the population of DNA in the reaction mixture becomes dominated by a single DNA
fragment of X nucleotides long (depending on the position of the primer sequences). Adapted
from Molecular Biology ofthe Cell 3rd edition.
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to each tube to avoid evaporation during thermal cycling. Amplification was
performed in a thermal cycler (Gene E, Techne Ltd., Cambridge, England). The
cycling parameters and the PCR conditions for each set of oligonucleotide primers are
shown in table 2.
Table 1: Primer sequences used in the amplification of the polymorphic sites in
COMT and SC'L6A4.
Gene/
Polymorphism
Primer Length Sequence Reference
name bp
COM7iN/aIJI CFP 20 5' -tcaccatcgagatcaacccc- 3 ' Karayiourgou et al..
CRP 19 5' -acaacgggtcaggcatgca- 3' 1997
COMT/ERE.o ERE6-F 20 5' -agagtctaggggtctgggga-J' Present Study
ERE6-R 20 5' -aaggtcctgctgtgctgact -3 '
SLC6A4/5-HTILPR JP 24 5' -atgccagcacctaacccctaatgt-J' GeIcrnter et al.. 1997
GR 20 5'-cgaccgcaaggtgggcggga-3'
Abbreviation
COMT: catechol-O-methyltransferase
ERJ';6: oestrogen response element 6
5-HTTLPR: serotonin transporter-linked polymorphic region
bp base pair
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Table2: peR conditions used in amplification of polymorphic sites in COMT and
SCL6A4.
Primer set Polymorphism [MgCh] TO Time TA Time TE Time
mM °C sec °C sec °C sec
CFP/CRP COMl/iV/alll 1.5 94 30 60 30 72 30
ERE6 FIR COMTlERE6 1.5 94 30 62 30 72 30
JP/GR 5-HlïL1'R 1.5 94 30 66 30 72 30
The thermo cycler was set to perform 30 amplification cycles for all polymorphisms
genotyped in the present study.
Abbreviation
('OMT: catechol-O-methyltransferase
ERE6: oestrogen response element 6
5-HT71,PR: serotonin transporter linked polymorphic region.
TO: denaturing temperature
TA: annealing temperature
TE: extension temperature
sec: seconds
mM millimolar
o C degrees Celcius
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2.5. GEL ELECTROPHORESIS
2.5.1. 12% non-denaturing polyacrylamide gel electrophoresis
Non-denaturing polyacrylamide gels were used for size separation of PCR products
(section 2.4) and restriction enzyme digests (section 2.6.1), using a 12%
polyacrylamide solution (Appendix I).
2.5.1.1. Casting the gel
The gel (Appendix 1) was cast between two IOOmmx 80mm glass plates. The plates
were washed with Cal-liquid hand soap (Cal-Chern, R.S.A.), rinsed with tap water
and dried using paper towel. The surfaces of the two plates were then sprayed with
70% ethanol and dried again with paper towel. One millimetre spacers were placed on
either side of the back plate and the front plate was then placed on top of the spacers.
The plates were held in place using clamps, and the sides and bottom of the plates
were then sealed using gel-sealing tape (SIGMA, Germany). The gel solution
(appendix I) was then poured between the assembled plates and the well-forming
comb was inserted. The gel was left to set for about 20 minutes before
electrophoresis.
2.5.1.2. Electrophoresis
After the gel had set, the gel-sealing tape around the sides and bottom of the gel was
removed. The gel was then clamped into the gel electrophoresis apparatus (Scigen
verticle mini apparatus, Whitehead Scientific, R.S.A.) and the buffer chambers filled
with 1 x TBE electrophoresis buffer (appendix I).
Bromophenol blue dye (Zul) was added to each of the samples to be electrophoresed.
The samples were then electrophoresed for Ilf2- 2 hours at 150 volts.
2.5.1.3. Silver staining
After completion of electrophoresis, the electrophoresis apparatus was dismantled and
the gel removed. The gel was then placed in a container containing 50mlof solution B
(0.1% AgN03) and gently shaken for 10 minutes. Solution B was carefully decanted
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and the gel rinsed with water. Fifty millilitres of Solution C (appendix I) was then
poured into the container, to cover the gel, which was gently agitated until stained
bands could be seen. The gel was then viewed on a white light illuminator (Lauda
thermostat, Germany) and photographed using a video printer (Sony, Japan)
2.5.2. Mutation analysis by PCR- single strand conformational polymorphism
(PCR-SSCP) analysis.
Single-strand conformational polymorphism analysis is a rapid and sensitive method
of detecting sequence variation (Orita et al., 1989). Single stranded DNA has a folded
conformation, stabilised by intrastrand interactions, which determines its mobility
under PCR-SSCP conditions. Consequently, the conformation, and thus the mobility
of the single stranded DNA under PCR-SSCP conditions, is dependant on the
sequence (Orita et al., 1989). A single base change is enough to change the folded
conformation of the single stranded DNA and hence alter its mobility under SSCP
conditions. Thus, PCR-SSCP involves the detection of electrophoretic shifts of single
stranded DNA with sequence variation from the wild type sequence.
For each panel of samples analysed, a 10% mildly denaturing polyacrylamide gel with
5% glycerol (appendix I) was used for PCR-SSCP mutation screening.
2.5.2.1. Casting the gel
The gel (Appendix) was cast between 390mm x 290mm glass plates, which were first
washed with Cal-liquid hand soap (Cal-Chern, R.S.A), rinsed in tap water and wiped
dry with paper towel, after which the surfaces were sprayed with 70% ethanol and
wiped clean as before. Gelbond™ PAG polyester film (FMC, Bioproducts, Rockland,
Maine, USA) was attached to the back plate by its hydrophobic side, to facilitate this,
70% alcohol was lightly sprayed onto this plate. The hydrophilic side of the
Gelbond™ was exposed so that, when the gel solution was poured, the two would
bond covalently, thus creating a solid support for the gel for subsequent silver
staining. The front plate was silinised with paper towel spotted with Wynn's C-THRU
windshield rain dispersant (Wynn Oil S.A. Pty Ltd,SA)
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One-millimetre spacers were placed on either side of the Gel bond-covered back plate
and the front plate then placed on top with the C-THRU-coated side on the inside. The
edges, on the sides and bottom of the plates, were sealed with gel-sealing tape
(SIGMA, Germany), after which the casting rubber boot (S2 casting boot, Life™
Technologies, UK) was fitted for further sealing. The gel solution was poured with
the glass plate assembly slanted at an angle. Immediately thereafter, the glass plates
assembly was laid down horizontally, a square-tooth, well-forming comb fitted, the
plates clamped and the gel allowed to set for ~ 1hf.
2.5.2.2. Electrophoresis
Thereafter, the casting boot, the sealing tape at the bottom of the plates and the comb
were removed, in this order. The glass plate assembly was mounted vertically on the
electrophoresis apparatus (Omeg Scientific, R.S.A), moved to the cold room (4°C)
and O.5xTBE (appendix I) buffer added to the reservoir tanks. The wells were washed
with buffer to remove any residues, and the denatured PCR sample (denatured at
94°C for 2 minutes) immediately loaded. Electrophoresis was carried out in O.5x TBE
buffer, at a constant power of SOWovernight at 4°C.
2.5.2.3. Silver Staining
Following electrophoresis of samples on the gels, the glass assembly was dismantled
and the gel still supported by the Gelbond™, was silver stained as discussed in section
2.5.l.3.
2.6. GENOTYPING
Polymorphisms can be detected in a variety of ways, depending on the type of
polymorphism. In the present study, two known polymorphisms were investigated.
Each of these polymorphisms required a different detection method.
The COMTlNlaIlI polymorphism is the result of a G to A transition and which creates
a restriction site for the restriction endonuclease Nlalll (Karayoirgou et al., 1997). It
is, therefore, possible to detect alleles of this polymorphism based on the presence or
absence of the restriction enzyme site. This technique is referred to as Allele Specific
Restriction Enzyme Analysis (ASREA)
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The 5-HTTLPR polymorphism, on the other hand, does not affect a restriction enzyme
site. This polymorphism is represented by a 44 bp insertion or deletion. Detecting the
different alleles in this type of polymorphism involves peR amplification of the target
region, followed by gel electrophoresis. The allele containing the 44bp insertion
yields a larger peR fragment than the allele without the insertion. Thus the detection
of 5-HTTLPR polymorphism is purely based on the differences in size between the
generated peR fragments representing each allele.
Another aim of this study was to determine whether FRE'6 in COMT is polymorphic.
In order to detect an unknown polymorphism or mutation, peR-SSep can be used.
This technique involves Pf'R amplification of the target region of interest followed by
ssep analysis.
2.6.1. ALLELE SPECIFIC RESTRICTION LENGTH POLYMORPHISM
(ASREA) ANALYSIS OF COMTlNlaIII POLYMORPHISM
peR-based allele specific restriction enzyme analysis was used to screen oeD
patients and control individuals for the previously reported NlaIII polymorphism in
exon 4 of the COMT gene.
Five microlitres of the amplified peR-product was aliquoted into a 500~1 eppendorf
microfuge tube. To this, l ul of a lOx Niaill buffer (New England Bioloabs), O.5U
NlaIII restriction enzyme (New England Biolabs) and water to a final volume of 1Oul
were added. The mixture was incubated at 37°e for 3 hours to allow digestion to
proceed. Fig lOshows the expected sizes of the digested products.
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CAICi ....~I----- NlaIII recognition
sequence
NlalII restriction site
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68bp Bbp 14bp
-+ 95bp ~ cor«
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Fig 10: Expected size fragments generated by digestion of COMTlNlaIlI
amplified product with NlaIlI restriction enzyme. The red arrow indicates the
position of a non-polymorphic MaIlI restriction site in the amplified region
2.6.2. Genotyping of 5HTTLPR polymorphism
The region containing the 44bp (lIs) polymorphism was amplified from genomic
DNA using the primer set 5-HTTLPR (JP and OR) shown in table 1 under the PCR
conditions shown in table 2. Alleles were then size-separated by electrophoresis in
12% polyacrylamide gels. Each sample was then genotyped according to the presence
of an insertion or deletion.
Meta-analysis of SLC6A415-HTTLPR polymorphism.
The meta-analysis of the 5HTTLPR polymorphism was performed usmg a
combination study of subjects shown in table 3 and subjects from a study by Bengel et
al (1999), which consisted of 75 unrelated Caucasian OCD patients (39 male and 36
female), all of whom underwent the Structured Clinical Interview for DSM-III-R as
well as the Yale-Brown Obsessive-compulsive scale (Y-BOCS), and 397 unrelated
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healthy controls (Bengel et aI., 1999). The data from the present study and the above
mention study was pooled and statistical analysis was performed.
2.6.3. PCR-SINGLE STRAND CONFORMATIONAL POLYMORPHISM
(PCR-SSCP) ANALYSIS OF COMTlERE6
The region of COMT containing E1lli6 was subjected to PCR-SSCP analysis to
determine whether a polymorphic site within ERE6 existed (section 2.5). Mobility
shifts detected were then sequenced (discussed in the next section).
2.6.4. SEQUENCING
A mobility shift detected by PCR-SSCP analysis indicated the presence of sequence
variation in the COMT/ERE6 PCR-amplified product. In order to confirm the
presence of a sequence variation and determine what the variation was, three samples
with mobility shifts were sequenced.
2.6.4.1. Purification ofPCR-fragment.
Before sequencing any PCR product, it is important to purify the product in order to
avoid generation of incorrect sequence data.
The COMT/ERE6 PCR products were purified using the QIA quick gel extraction kit
(Qiagen, Germany), following manufacturer's instructions. The COMT//<_,RE6
amplified products were loaded onto a 2% agarose gel, containing ethidium bromide,
and electrophoresed for 1 hour in 1x TBE running buffer at room temperature. The
DNA was visualised on a longwave transilluminator (3UV transilluminator,
California USA) and the correctly sized fragment (as indicated by the )JJstI molecular
weight marker) excised from the gel using a sterile scalpel blade. The gel slice was
placed into a I.5ml Eppendorf microfuge tube and weighed. Three volumes of the
QX 1 butTer was added to 1 volume gel.
The gel slice in the QX 1 buffer (Qiagen, Germany) mixture was incubated for 10
minutes at 50°C or until the gel has completely dissolved. One gel volume of
Stellenbosch University http://scholar.sun.ac.za
59
isopropanol was added to the sample and gently mixed (in order to increase the yield
of small DNA fragments). A Qiaquick spin column was placed into a provided 2ml
collection tube and the sample was applied to the column and centrifuged in a
Beckman microfuge (Germany) at 13000rpm for one minute, in order for the DNA to
bind the column. The flowthrough was discarded and the column was replaced in the
same collection tube. Buffer QX1 (500111) was then added to the column and
centrifuged at 13000 rpm for one minute to remove all traces of agarose. Fifty
microlitres distilled water was added to the column, in order to elute the DNA. The
DNA was subsequently dried in a Speedivac (Savant, New York, USA) and was
resuspended in 10111of distilled water.
2.6.4.2. Automated sequencing
Both coding and non-coding strands of the PCR-fragment containing ERE6 was
directly sequenced using primers ERE6-F and ERE6-R (table 1) at the Department of
Genetics at the University of Stellenbosch, Stellenbosch, South Africa, using an ABT
TMPrism 377 automated sequencer.
2.6.4.3.Genotyping
As the polymorphism detected in this region did not affect any restriction enzyme site,
the SSCP banding pattern was used to separate the alleles. The SSCP banding pattern
was compared to sequence data, to determine which banding pattern represented
which allele.
2.7. STATISTICAL ANALYSIS
2.7.1. Calculating allele frequencies
The frequency of high (H) and low (l~)alleles of the COMFNlall1 polymorphism,
long (I) and short (s) alleles of 5-HTlIYR and C and T alleles of COM7//,R/'.:6 alleles
were calculated by dividing the total number of a particular allele by the total number
of chromosomes in the study group.
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2.7.2. Calculating expected allele freguencies
In order to predict the expected distribution of alleles at each of the loci in the study,
the Hardy-Weinberg formula was used. This formula predicts that p2+2pq+q2=1
(where p= frequency of allele A and q= frequency of allele B), if the genotypes in the
population are in Hardy-Weinberg equilibrium. The observed allele frequencies at
each locus were inserted into the Hardy-Weinberg equation, while the expected
number of genotypes was calculated by multiplying the values of p2 (AxA), 2pq
[2(AxB)] and q2 (BxB) by the total number of individuals genotyped in the control
and OCD patient groups.
2.7.3. x2 analysis of the expected versus observed genotype freguencies
To determine whether the genotype frequencies were in Hardy-Weinberg equilibrium,
the expected and observed genotype frequencies for OCD patients and control
individuals were displayed in a 3X2 contingency table and X2 analysis performed
using the Software Programme for Social Science (SPSS).
2.7.4. Determination of the association between OCD and the polymorphisms at
the various loci
The frequency of genotypes observed at each locus for OCD patients and that of the
control individuals were displayed in a 3x2 contingency table. Chi-square analysis
was performed using the SPSS to determine the statistical significance differences
between these values.
PART II: IMMUNOLOGICAL STUDY
2.8. STUDY SUBJECTS
Subjects recruited for this part of the study were between the ages of 9 and 65 years.
Patients with OCD, TTM, PO and SP were recruited from the MRC unit on Anxiety
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and Stress Disorders. Control individuals were recruited as described in section 2.1.
Diagnostic criteria for each subjects is as described in section 2.1. Inclusion criteria
for affected individuals were a predominant DSM-IV diagnosis of OCD, TTM PD or
SP. The control group had no past or current psychiatric disorder, RF or Sc. The
psychiatric control were further stratified into two groups namely, the anxiety disorder
group, in which patients had a predominant DSM-IV diagnosis of either SP or PD,
and a OC spectrum disorder group, in which patients had a predominant diagnosis of
TTM.
2.9. BLOOD COLLECTION
Blood was collected as described in section 2.2.
2.10. FLOURESCENCE ACTIVATED CELL SORTING (FACS)
Flow cytometry allows investigators to analyse cells at the single cell level by
measuring specific characteristics of the cells. On each cell, several characteristics can
be measured. These include the forward scatter (FSC), side scatter (SSC) and
fluorescence (FL). Prior to analysis, the cells are stained with two antiboby-
conjugated dyes, which have the same excitation range, but different emission
maxima.
During analysis, cells are separately sucked though a thin capillary tube and shot with
an argon laser beam with a wavelength of 488 nm. The antibody-conjugated dyes on
stained cells become excited and emit a light signal. In a flow cytometer, these signals
are proportional to the amount of light detected. The FSC and SSC detectors measure
the scatter of the light signal. Forward scatter is a measure of cell size, while SSC is
the measure of the granularity of the cell population. All these data are then
represented on dot plots or histograms (fig 17) using Cell Quest software.
2.10.1. LABELLING OF CELLS
Labelling of cells always took place within 6 hours of blood being drawn. Fifty
microlitres of whole blood was aliquoted into a 3ml plastic Falcon FACS tube. To the
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blood, 20J.l1of phycoerythin-conjugated monoclonal HLA-DR (Anit-MHC Class II)
was added to identify B cells. The mixture was incubated in the dark at room
temperature for 20 minutes, after which 2ml ice cold phosphate buffered saline (PBS)
was added. The sample was gently mixed by carefully inverting the tube. This was
followed by centrifugation at 300rpm for five minutes. The clear supernatant was
discarded and to the pellet, 20J.l1FITC-conjugated antimouse IgM antibody was added
for detection. The tube was again incubated in the dark for 20 minutes at room
temperature, followed by another PBS wash cycle (addition of PBS, centrifugation,
discarding of supernatant). Fifty microlitres D8/17 antibody was aliquoted into the
tube, which was again incubated in the dark for 20 minutes. This was followed by
another PBS wash cycle. To the pellet, 2ml FACS lysing solution was added and the
sample was mixed by vortexing (Vortex Genie2). The sample was incubated in the
dark for 10 minutes at room temperature followed by centrifugation at 300rpm for 5
minutes. The supernatant was discarded and the pellet resuspended in 500J.l1FACS
fixing solution. The sample was then either immediately used for flow cytometry or
stored at 4 C until needed.
2.10.2. FLOW CYTOMETRY
The analysis of the preparation was based on the lymphocyte scatter gate (low side
scatter and high forward scatter) and within this gate, positivity for MHC Class II was
determined. This identified B-cells falling within the gate. Within this gate the
expression of D8/I 7 positive B cells was determined. The percentage of B-cells
expressing D8/I 7 was determined using a Facscalibre™ flow cytometer (Beckton
Dickenson) and analysed by the Cell Quest software program at the Department of
Medical Microbiology, University of Stellenbosch.
2.10.3. STATISTICAL ANALYSIS
Dr. Carl Lombard at the Medical Research Council, South Africa, performed analysis
of variance and post-hoc Tukey procedure for correction for multiple testing on the
08/17 data generated
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CHAPTER3: RESULTS
3.1. Recruitment of subjects
The numbers of subjects analysed in each section of this study are shown in tables 3
and 4.
The COM!' and the ,~TC6A4 studies were run concurrently, therefore, each study
group genotyped for COMTNfaIII was also genotyped for 5-H!'TLPR. The DNA
samples used in these two investigations were also used by other researchers for
different studies. These studies included association studies of other candidate genes
by another investigator in our laboratory and, furthermore, 500111of each sample was
couriered to investigators in the United States for collaborative studies. As a result of
this, 14 OeD patients' DNA samples were depleted by the time the COMT/ERE6
study had started. This accounts for the unequal number of patients analysed in each
study. Subsequent results (see section 3.2.1.) obviated the need to collect further
control samples for the COMTINlalII study, but required the recruitment of more
control individuals for the 5-HT17)LR study (section 3.3.). The same control samples
used in the COMDNfallI study were also used in the COMT/£"RE6 study, however,
six of these control samples were also depleted because of their use in concurrent
studies. For these reasons, there are discrepancies between the numbers of control
individuals used in each study.
When the immunological study started, many patients had already been recruited for
the genetic study and had donated blood. Subsequently, many of these patients were
either unwilling or unavailable to donate more blood for the immunological study.
This accounts for the discrepancy between the patient numbers in the genetic and
immunological studies.
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Table 3. Number of OCD patients and control individuals recruited for genetic
studies
Number of study subjects
OCD patients Control individuals
Polymorphism
Studied
COM TlNlaIII
Total Male Female Total Male Female
54 26 28 54 26 28
COMTlERE6 40 25 15 48 20 28
5-HTILPR 54 26 28 82 40 42
OCD: Obsessive-compulsive disorder
Table 4. Number of OCD patients and control individuals assessed in
immunological study
Number of study subjects
Total Male
OC']) 26 12
Healthy control 26 10
Psychiatric controls: SP and PD 16 10
TIM 22 3
Female
14
16
6
19
OCD Obsessive-compulsive disorder
SP: Social phobia
PD: Panic disorder
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TTM: Trichotillomania
3.2. Genotyping of polymorphisms in COMT
3.2.1. ASREA of COMTlNlalII polymorphism
PCR amplification of the region flanking the COMTWlaIII polymorphic site in exon 4
of COMT yielded a 95 bp fragment (fig. Il). This fragment also contains a non-
variant Nlalll restriction enzyme site, which served as an internal control to monitor
enzyme activity and as an indication of incomplete digestion (fig 10). Therefore,
digestion of this product with NIall I restriction enzyme yielded three fragments of 68
bp, 14 bp and 13 bp in size for the L allele or two fragments of 82 bp and 13bp for the
H allele. Consequently, in an H/L heterozygous individual, four fragments are
expected. However, the 13 bp and the 14 bp fragments were not visualised since they
were electrophoresed from the gel because of their small size (fig 12).
In the present association study, both patient and control groups were in Hardy-
Weinberg equilibrium (table 5). A statistically significant difference was detected in
genotype distribution of the COMT/NlallI polymorphism between the two groups,
with a predominance of the H/L genotype in the OCD patient group (p=0.0017) (table
6). When the study sample was stratified according to gender, a statistically
significant difference was generated between either male or female patients and
controls (p=0.043 and 0.029, respectively) (table 6). There was, however, no
statistical difference between the distribution of Hand L alleles in OCD and control
groups (0.44 H: 0.56 L, OCD; 0.46 H: 0.54 L, control) (table 7).
3.2.2. COMT/ERE6 analysis
3.2.2.1. Detection of novel sequence variant
The amplified 150 bp PCR product containing COMTI.,Rlj'6 is shown in figure 13.
The PCR fragments were subjected to PCR-SSCP analysis to detect the presence of
any sequence variation. A frequently occurring mobility shift was detected in both
OCD and control groups (fig 14). Subsequent sequence analysis of three individuals
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revealed a single nucleotide change 8 bp 5' to ERE6 (fig 15), in which the variation is
represented by a C-T transition. Single nucleotide polymorphism (SNP) database
1 2 3 4 5 6 M
...... 75bp
Non-specific bands ____.
95bp ---"11.-
Fig 11: peR amplification of exon 4 containing COMT/NlaIII polymorphism.
12% polyacryalamide gel showing the fragment size generated by PCR using the
primers 5' -tcaccatcgagatcaacccc- 3' and 5' -acaacgggtcaggcatgca- 3' . Lane M:
Molecular weight marker (WNA digested with Pst! restriction enzyme; the 75bp
fragments indicated by blue arrow). Lanes 1-6: 95 bp peR fragment (indicated by
black arrow) containing the Niall! polymorphism. Because of the sensitivity of silver
staining, many non-specific DNA bands (indicated by red arrow) are visualised,
which would not normally be visible on ethidium bromide-stained gels.
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Non-specific bands
82 bp
68bp
HlL HIH UL HlLHIL UL HlH
Fig 12: ASREA of reported COMTlNlalII polymorphism.
A representative 12% polyacrylamide gel of NlaIII restriction enzyme digest of
COMT exon 4 digested PCR amplified products. Lane M: Molecular weight marker
("-DNA digested with PstI); Lane I : undigested PCR product; Genotypes in Lanes 2
and 7: HIH; Lanes 1,4 and: HIL; Lanes 3 and 6: LIL. Higher molecular weight non-
specific bands can also be seen (red arrow). The band indicated by the blue arrow is
bovine serum albumin, which is present in the restriction enzyme reaction mix.
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Table 5. Comparison of expected and observed distribution of COMTlNlaIlI
genotypes in OCD patients and control individuals by ·l analysis.
Stuay group H/L P-valueNumber H/H LiL
OCD Expected 10 27 17 0.09
Observed 5 38 11
Control Expected 11 27 16 038
Observed 15 20 19
Table 6: COMT genotype distribution in patients and controls
OCD Patients (N=54) Control Individuals (N=54)
COMTNlaIII Total Male Female ITotal 3Female
Genotype
H/H 5 (9.3%) 4 (15.4%) 1 (3.6%) 15 (28%) 9 (34.6%) 6 (21.4%)
H/L 38 (70.4%) 18 (69.2%) 20 (71.4%) 20 (34.6) 9 (34.6%) 11 (39.3%)
11 (20.3%) 4 (15.4%) 19 (35%) 8 (30.8%) 11 (39.3%)
IX2= 12.72; 2 df; p=O.0017
Genotype percentages shown in brackets
2Male OCD versus control p=O.043
J Female OCD versus control p=O.029
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Table 7: COMT/NlaIII allele frequencies in patient and control individuals
Hallele L allele
OCD patients
Control individuals
0.44
0.46
0.56
0.54
,.l= 0.2; 2df; p=0.89
searches at http.z/www.ncbi nlm nih.gov/SNP/get_html revealed that the detected
sequence variation (hereafter refered to as COMTP2-1040-C/T) had not previously
been reported.
3.2.2.2. Genotyping of novel sequence variant
Since the COMTP2-1040-C/T polymorphism did not affect any restriction enzyme
site, patient and control samples were genotyped for the CIT change using PCR-SSCP
banding patterns (fig 14). Both OCD and control groups were in Hardy-Weinberg
equilibrium (table 8) as indicated by the p-values ofO.96 (OCD) and 0.41 (control),
when comparing observed and expected genotype distribution.
Chi-square analysis, applied to the data to determine whether this variation was
associated with OCD, revealed no significant difference in the genotype distribution
(p=0.45) or allele frequency (p=0.26) between patient and control groups (table 9).
Allele frequency data suggested that this polymorphism is commonly occurring
within the study population (i.e., in more than 1% of the population) and therefore the
COMTP2-1040-ClTpolymorphism can be classified as an SNP. The COMTP2-1040-
CIT polymorphism was submitted to the SNP database at
(Accession number: AFOOI102).
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M 1 2 3 4 5 6
150 bp
Fig 13: peR amplification COMT promoter region 2 containing ERE6.
12% polyacrylamide gel showing fragment size generated by using primers
5'-agagtctaggggtctgggga-3' and 5'-aaggtcctgctgtgctgact-3' in PCR. Lane M:
Molecular weight marker (ADNA digested with Psti restriction enzyme); Lanes 1-6:
150 bp PCR fragment of COMT promoter region 2 containing ERE6
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111
..-
Fig 14: PCR-SSCP analysis of ERE6-containing region on a 10% mildly
denaturing polyacrylamide gel with 5% glycerol. SSCP mobility shifts are
indicated by arrows above the lanes. The arrows each indicate a different genotype of
the detected sequence variation. The purple arrow shows the CIC genotype (C allele
shown in fig 15 A), the red arrow shows the TIT genotype (T allele shown in fig 15
B) and the black arrow shows the CIT heterozygote genotype
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5' ERE6
11 + 21 36 U 51 "
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GGCTAGTGGGGCCGGTGCCTGGTGACCTCGGGAG
C 5' 3'
GGCCAGTGGGGCCGGTGCCTGGTGACCTCGGGAG
Fig 15: Partial sequence of promoter region of COMT containing ERE6. Vertical
arrows show the position of the novel C-T transition. Magenta bars represent the
position of the ERE6. A represents the T allele, while B represents the C allele on the
coding strand. In A, the sequence text shows a 'Y' at the position of the
polymorphism. Looking at the sequence trace, however the red peak below the 'V'
indicates the presence of a 'T' at that position. C shows a schematic representation of
the sequence trace. The purple rectangle indicates the position ofthe half-palindromic
ERE6. The magenta font indicates the half-palindrome ERE consensus sequence. The
top sequence represents the T allele, while the bottom sequence represents the C allele
(as indicated by the blue font).
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Table 8. Comparison of expected and observed distribution of COMTP2-}04()-
CIF genotypes in OCD patients and control individuals by l analysis
Number of subjects
Study group cc P-valueNumber
OCD Expected
Observed
Expected
Observed
29
30
24
30
Control
CIT TIT
10
9
20
16
0.96
4
2
0.41
OCD: Obsessive-compulsive disorder
Table 9: COMTP2-}040-CIF genotype distribution and allele frequencies in OCD
patients and control individuals
1 Genotype distribution 2Allele frequency
CIC CIT TIT
OCD 30 (75%) 9 (22.5%) 1 (2.5%)
Control 30 (62.5%) 16 (33.3%) 2 (4.2%)
Total C T
40 0.86 0.14
48 0.79 0.21
1X2= 1.58; 2df; p=0.45
Genotype percentage shown in brackets
Of.D: Obsessive-compulsive disorder
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3.3. Genotyping of 5-HTTLPR polymorphism
3.3.1. Analysis of data generated in the present study
Pf'R amplification of the region of SLC6A4 encompassing 5-HTILPR yielded a 419
bp fragment for the III genotype and a 375 bp fragments for the sis genotype, with the
l/s heterozygote yielding two fragments 419bp and a 375 bp in size (fig 16). Both
experimental and control groups were in Hardy-Weinberg equilibrium (table 10).
Table 11 shows the distribution of genotypes and allele frequencies observed in the
present study. No statistical differences between the observed genotype frequencies
(p=0.19) or allele frequencies (p=0.067) were detected between the OeD and control
groups.
3.3.2. Meta-analysis of 5-HTTLPR
Because of the relatively small sample size analysed in the present study, a meta-
analysis of 5-H17IPR was performed, in order to improve the power to detect a
statistically significant difference between patients and controls. The meta-analysis
consisted of the present study (table 11) and data generated by Bengel et al., (1999)
(table 12), thereby examining a total of 129 OeD patients and 479 control individuals
(table 13).
The results of the meta-analysis showed that there was no significant difference in the
distribution of 5-H17LPR genotypes (p=0.11) and allele frequencies (p=0.56)
between patient and control groups.
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M 2 3 4 5 6 7 8 9 10 11
II ..
419bp
375bp
s/s 1;\, lis I/I l/s sis lis Lil L/I sis lis
Fig 16 peR of SLC6A4/5-HTTLPR . 12% polyacrylamide gel showing fragments
generated by peR using pnmers 5' -agagtctaggggtctgggga-3 'and 5'-
aaggtcctgctgtgctgact-3'. Lane M: molecular weight marker (ADNA digested with
Pstl); Lanes 1,6,9 and 10: sis; Lanes 2,3,5 and 7: LA; Lanes -I and 8: Il
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Table 10: Comparison of expected and observed distribution of 5-HTTLPR
genotypes in OCD patients and control individuals by X2analysis
Number of subjects
Study group Numbers I/I lis P-value
OCD Expected
Observed
Expected
Observed
11
11
27
27
27
27
40
39
16
16
15
16
1.00
Control 0.98
Table 11: Distribution of 5-HTTLPR genotypes and allele frequencies in oeD
patients and control individuals of Afrikaner descent
'Genotype distribution 2Allele frequency
I/I sis Total I s
OCD Il (20.4%) 27 (50%) 16 (29.6) 54 0.45 0.55
Control 27 (32.9%) 39 (47.6) 16 (19.5%) 82 0.57 0.43
1X2= 3.29; 2df; p=0.19
Genotype percentage shown in brackets
2l 2.88; 2df; p=0.067
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Table 12. Distribution of 5-HITLPR genotypes in study by Bengel et al (1999)
IGenotype distribution 2Allele frequency
Study group III lis SIS Total I s
OCD 35 (46%) 29 (38.7%) Il (14.7%) 75 0.66 034
Control 98 (24.7%) 214 (53.9) 85 (21.4%) 397 0.51 0.49
I X2= 5.19; 2df; p=0.023
Genotype percentage shown in brackets
Table 13: Distribution of 5-HTTLPR genotypes and allele frequency in meta-
analysis
'Genotype distribution 2Allele frequency
I/I Is SiS Total I s
OCD 46 (35.7%) 56 (434%» 27 (209%) 129 0.57 0.43
Control 125(26.1(%) 253(52.8%) 101(21.1.%) 479 0.53 0.47
I X2 = 4.29; 2df; p=O 11
Genotype percentages shown in brackets
2 X2 = 0.32; 2df; p=0.56
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3.4. Analysis of D8/17 expression
Figure 17 shows a representative FACS analysis data set determining the percentage
08/17 expressing B-lymphocytes. Analysis of variance of mean D8/17 expression
showed a significant difference between groups (F=1316, df=84, p=O.OI), with no
age (p=0.39) or sex (p=0.81) effect. D8/17 levels were found to be significantly
higher in the OCD patient group (22.95%) than in the group with anxiety disorders
(9.97%)(p < 0.0001), or the normal control group (16.09%) (p = 0.041), but not the
TTM group (16.05%)(p =0.097)(Table 14).
Post-hoc Tukey procedure for correcting for multiple comparisons revealed only one
significant difference; 08/17 expression was significantly higher in the OCD group
than in the anxiety disorder group (p=0.006) (table 15).
The OCO study group was stratified according to age of onset of disease. Fifteen of
the twenty-six OCD patients had an onset of symptoms after the age of 10 years (late
onset). The expression levels ofD8/17 showed no significant difference between early
and late onset of disease (table 16). An association with past or present motor or vocal
tics was also evaluated, therefore the OCD study group was restratified according to
whether they had a history of comorbid tic disorders. The data shows that vocal or
motor tics (3/26) in OCD patients were also not associated with higher D8/17
expression (table 16).
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Table 14: Analysis of expression of D8/17 in OCD, psychiatric and non-
psychiatric control groups by Analysis of Variance (ANOVA)
OCD Normal
Controls
SAD/PD TTM
% D8/17 22.95
(±14.2)
16.09
(±8.5)
9.97
(±4.3)
16.05
(±13.9)expression
'p-values p = 0.041 p = 0.0001 p = 0.097
1 p-value of OCD versus other groups
Table 15: Expression of D8/17 in OCD, psychiatric and non-psychiatric control
groups corrected for multiple testing by the post-hoc Tukey procedure
Study groups
OCD Normal SPIPD TTM
Control Control Control
Number of
subjects
26 26 16 22
% D8/17
expression
22.95
(±14.2)
16.09
(±8.5)
9.97
(±4.3)
16.05
(±14)
p_ value I 0.20 0.006 0.26
I p-value of OCD versus other groups
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Table 16: D8/17 expression in the OCD group, stratified according to age of
onset and lifetime history of tics
Age of onset 1
Early Late Present or Absent
history
Number of Il 15 3 23
subjects
(26)
% D81l7 21.85 23.76 12.93 24.26
expression (±15.5) (± 13.7) (±12.6) (±14.1)
(mean)
p-value 0.74 0.20
) Late onset defined as onset after the age of 10 years.
2 Lifetime history of vocal or motor tics.
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Fig 17. A typical flow cytometric measurement of the level of D8/17 expression.
A: Dot plot showing the forward scatter (FSC) (x-axis) and the side scatter (SSC) (y-
axis) of each cell analysed in this representational FACS analysis. Lymphocytes are
characterised by low SSe. The lymphocytes are gated for analysis (blue arrow).
B: Histogram showing the gated lymphocytes in A. The number of cells (xlOO) is
shown on the Y-axis, while the HLA-DR fluorescence (FL2-H) is shown on X-axis.
HLA-DR is B-cell specific and thus all B-cells are stained with this dye. The region of
the histogram marked Ml and Rlshows the amount of B-Iymphocytes among the
lymphocyte population gated in A, while the region to the left of M 1 and Rl indicate
T-Iyrnphocytes. C: Histogram showing the number of D8/17 expressing B-
lymphocytes (M 1) within the population of B-Iymphocytes under regions Ml and Rl
in B. D: A tabular representation of the histogram in B. E: A tabular representation of
the histogram shown in C. The blue box indicates the percentage D8/17 expressing B-
lymphocytes.
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CHAPTER4: DISCUSSION
PART I: GENETIC STUDY
In the present study, the possible roles of two candidate genes in OCD pathogenesis
were investigated using a case-control association study design. The first candidate
gene screened was COMT, which encodes the MB-COMT, and S-COMT, that is
responsible for the degradation of a variety of catechol neurotransmitters (section
1.2.4.2.4). The second gene investigated was SLC6A4 that encodes the 5HTT protein
responsible for the reuptake of 5HT during neurotransmission (section 1.2.4.2.4). The
following section discusses the results of the present association study between these
two genes and OCD in the Afrikaner population.
4.1. COMT/NlaIll
The results generated by the present association study showed an association between
the H/L genotype and OCD in the Afrikaner population and this association was
found to be gender independent (table 6). Interestingly, these results differ from those
of a previously reported association study, where homozygosity for the L allele was
associated with OCD in males (Karayiourgou et al., 1997). The biological basis for the
observed sex-selective association reported by Karayiorgou and colleagues is still
unclear. The authors speculated that since studies have shown that oestrogens can
reduce COMT activity epigenetically, females may have evolved mechanisms
compensating for their lower COMT activity levels. Therefore, they are relatively less
vulnerable to developing OCD in association with lower enzyme activity.
Explanations for the predominance of the heterozygous genotype in the present study
are also speculative. One possible explanation is that genetic or environmental
interacting modulators influence this association. There is an increasing body of
evidence that suggests that specific environmental determinants are important
mediators of OCD (Swedo et aI., 1998, Niehaus et aI., 1999). Another possibility,
which could account for the association seen in the present study, is that there may be
Stellenbosch University http://scholar.sun.ac.za
86
another genetic susceptibility factor present in this homogeneous population that
predisposes individuals with intermediate COMT enzyme activity levels to develop
OCD.
However, although the data generated in the present study and the work of
Karayiorgou et al., (1997) differ in respect to OCD susceptible gender and genotype,
they both implicate the COMT gene in the pathogenesis of the disorder.
It is important to re-evaluate the findings of the present association study in a follow-
up study employing a second group of OCD patients and control individuals of
Afrikaner descent. Furthermore, the relatively small sample size may have lead to a
Typel error in the present study, thus re-evaluation studies will need to recruit more
samples in order to overcome this problem. Replication of the association generated
in the present study would confirm the involvement of COMT in OCD pathogenesis
in the Afrikaner population.
4.2. COMT/ERE6
Gender differences in clinical manifestations have been described for several
psychiatric disorders, including OCD (Castle et al., 1995; Lensi et al., 1996). These
differences have been attributed to the epigenetic hormonal influences that affect
disease processes.
Studies have shown that COMT activity is regulated by oestrogens via EREs within
the COMT gene promoter region (Xie et ar, 1999). In the present study, it was
hypothesised that if a variation occurs within EJU';6, an EJU~ which is crucial in
COMT regulation, COMT activity may be affected thereby increasing the risk for
OCD. The results of the present study identified a novel sequence variation 8 bp 5' to
ERE6 (fig IS), designated COMTP2-1040-C/T~ which, however, did not reveal an
association with OCD pathogenesis in the Afrikaner population (table 8).
Since an association was observed between OCD and the COM7ïNlalll functional
polymorphism, one would have expected to observe a similar association with
COMIP2-1040-C/T As these two polymorphisms occur within the same gene, they
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would be expected to be in linkage disequilibrium (LO) In the genetically
homogeneous population studied. In the present study, this was, however, not
observed.
The lack of information content of COMIP2-J040-C/T may explain why this
polymorphism and COMFNlaIII do not appear to be in LD. In a biallelic system,
such as the one investigated, SNP markers are generally informative enough to use in
analysis if the rarer allele has a frequency of at least 0.2 (Read and Strachan, 1996).
Upon genotyping 48 OCD patients and 40 control individuals for COMIP2-J040-
Crl', it was found that the C: T allele distribution was 0.82: 0.18 (table 9). Therefore,
this polymorphism may lack the necessary information content to detect any
significant association in the present study. Therefore it could be speculated that
COM7P2-J040-C/T, may be in LO with COMTINlaIlI, but did not generate the
statistical power to prove or disprove this hypothesis in the present study.
4.3.SLC6A4
The data generated in the present case-control study of OCD in the Afrikaner
population did not support the hypothesis of an association between genotype
distribution of the functional 5-HTTLPR in SLC6A4 and OCD (table 11).
As the present study may have lacked sufficient power to detect minor effects of
SLC6A4 on OCD pathogenesis, a meta-analysis of 5-HTTLPR genotype distribution
was performed that included data from the present study, as well as the study of
Bengel et al., 1999). Data generated in an association study by McDougle et al.,
(1998) was excluded from the meta-analysis as it employed a TOT design. The
studies by Ohara et al., (1998) and Nicollini et al., (1999) were also excluded from
the meta-analysis because they made use of a Japanese and a Mexican population,
respectively. The use of the latter two studies would confound the meta-analysis as
the frequency of I and s alleles in the Japanese and Mexican populations differ
significantly from that of the Afrikaner and North American Caucasian populations
(Ohara et al, 1998. Nicollini et al., 1999).
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If, as suggested by the data generated by Bengel et aI., (1999), 5-HT7IPR is involved
in OCD pathogenesis, the meta-analysis would have been expected to strengthen this
previous association. The fact that the combination of data yielded a non-significant
result could be attributed to one of a number factors. Firstly, it may be ascribed to the
underlying genetic differences between the two populations studied Even though
both populations studied were Caucasian, the Afrikaner population of South Africa
originated from a group of primarily Dutch, German and French descent (section
1.1.2.3), whereas the North American Caucasian population is made up largely of
Irish, Italian and eastern European settlers (htW~L~\_\\. (i!1ewQd~L.Qrg·)
Alternatively, it is possible that the role played by SLC6A4 in the pathogenesis of
OCD may be negligible, or even non-existent. At a low level of gene involvement, it
is possible that factors, which cannot be controlled in the experimental design, may
generate discrepant results in consecutive studies.
4.4. ASSOCIATION STUDIES IN PSYCHIATRY
As indicated in the previous section, population-based association studies often
generate conflicting results (Ohara et aI., 1998; Bengel et al., 1999), which authors
generally attribute to a variety of confounding factors although they frequently omit to
include study design or chance as explanations.
4.4.1. Underlying genetic differences
Difficulties in confirming positive or negative associations detected between a
specific candidate gene and a disease, in different studies, are often ascribed to
underlying genetic differences between populations. Indeed this is one explanation
offered in the present study (section 4.3) Our current understanding of complex
disorders, such as OCD, is that several mechanisms (genetic and environmental) may
playa role in the presentation of disease phenotype in different individuals (Zohar et
aI., 1987; Stein 2000). Taking into account the genetic and environmental differences
among population groups, it is possible that different combinations of environmental
and genetic mechanisms could contribute to disease pathogenesis in each population.
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The present study is being run concurrently with studies at the Genealogical Institute
of South Africa (GISA), who are tracing many of the Afrikaner cases and control
families, used in this study, back to their original founders. The study subjects
recruited in this study were classified as being Afrikaner if at least three of their
grandparents were of Afrikaner descent; which may have lead to genetic admixture
because of the ethnicity of the fourth grandparent. This raises the question of whether
the study population was sufficiently genetically homogeneous and this question is
currently being addressed by the GISA investigation.
Furthermore, it has been proposed (Stoltenberg and Burmeister, 2000) that the
interaction of a variety of genetic loci (some of major effect and others of minor
effect) contributes to disease pathogenesis in a variety of psychiatric disorders,
including OeD. It is therefore likely that different combinations of allelic variation in
different genes, interacting with one another and the environment, may lead to the
disorder in different population groups. This could account for the inconsistent data
generated in studies assessing the role of SLC6A4 and COMT in various association
studies using different population groups.
4.4.2. Statistical power
Statistical power and sample size are other confounding factors that could account for
the inconsistencies between association studies of specific candidate genes and
complex diseases.
The sample SIze required to reach statistical significance in genetic case-control
association studies is dependent on a number of interacting factors. These include i)
the power of the study (ie, the expression of the ability of the study to detect a true
effect if one exists and the ability to differentiate between a significant negative
association and an inconclusive result) and ii) the specific effect size (ie. the
contribution to disease pathogenesis made by the specific allelic variation under
investigation) (Berry et al., 1998).
It has been proposed as a convention that, when an investigator has no other basis for
choosing the desired power of the study, a value of80% be used, that is the ability to
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detect a 20% difference between two values. (Berry et al., 1998). It is also common
practice that the level of significance (ie., the p-value) be set at 0.05, that is with a
95% confidence level.
Therefore, in studying diseases of complex aetiology, it follows that the sample size
required to detect an association between disease and genes of major effect would be
considerably less than the sample size required to detect an association with genes of
minor effect. This explains why the present study was able to detect an association
between COMT/NlaIII and OeD using a relatively small sample. The association
study of COMT/NlaIII and Of'D by Karayiorgou et ai, (1997) used a sample of 78
OeD patients and 148 control individuals to show an association between COMT and
OeD. The results of the two above mentioned case-control association studies
together with the association found between COMT and OeD using family-based
methods (Karyiorgou, et al., 1998), using modest sample sizes, provides much
evidence for COMTbeing a gene of major effect in OeD pathogenesis.
On the other hand, the non-significant finding generated in the present study of Of'D
and 5-HTTLPR in SLC6A4 may have been the result of analysing insufficient samples
which did not allow the detection of a significant association (Type II error). As
previously mentioned, the contribution made by this gene to OeD pathogenesis may
be minor or non-existent. Under these circumstances, if one proposes that SLC6A4
does playa minor role in OeD pathogenesis, the sample size required to detect the
contribution made by this gene would be greater than the sample size used in the
COMT:NlaIII studies. In fact it can be calculated, the sample size required to detect a
20% difference the 5% significance level for the pooled 129 Of.D samples used in the
meta-analysis was 1444 control individuals. Thus, as only 479 controls were
genotyped, it can be reasoned that even the two studies used in the meta-analysis were
conducted using insufficient numbers to detect an association between OeD and
,)'LC6A4, if in fact it does exist. Furthermore, the positive association reported by
Bengel et ai, (1999) may have been a spurious result, which may be attributed to a
Type I error.
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However, it is important to realise that although increasing the sample size of the
study cohorts may generate statistically significant data, this may not always equate to
clinical relevance (Berry et ar, 1998).
The Afrikaner population andfuture association studies
Association studies to test the candidature of COMT and SLC6A4 as susceptibility
factors in OCD development in the Afrikaner population have generated divergent
findings in comparison with other study groups. This may be attributed to the inherent
genetic differences among population groups used in various association studies. It is
for this reason association studies between attractive OCD candidate genes and
clinically well characterised and matched subjects from a genetically homogeneous
population may help to further delineate the specific mechanism(s) that underpin this
complex disorder. To this end, the genetically homogeneous Afrikaner sub-population
of South Africa provides researchers with an invaluable investigative tool for further
studies (Niehaus et al., in press; Kinnear et al., 2000).
PART II: IMMUNOLOGICAL STUDY
4.5. DS/17
Our finding that B-lymphocyte 08/17 expression levels are not significantly higher in
OCD than in normal controls differs from previously reported data by Swedo et al.,
(1997) and Murphy et al., (1997). The latter two studies showed mean 08/17
expression to be significantly higher in the patient groups (mean, 22% and 29%,
respectively) versus the healthy control groups (mean, 9% and 8%, respectively)
(Swedo et al., 1997; Murphy et al., 1997). A preliminary study by our group has also
showed an association between increase 08/17 expression levels and OCD in the
Afrikaner population (Niehaus el al., 1999).
It is possible that the divergent results generated in the present study may have
resulted from important differences between the samples used in the two above
mentioned studies and the present study. The studies of Swedo el al., (1997) and
Murphy et al., (1997) focused on early onset OCD (11: childhood onset; 15: adult
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onset), and both included a high prevalence of patients with concurrent tics (24/27 and
21/30). Our OCD sample did not focus on childhood onset OCD and consisted of only
3/26 patients with a history of tics (table 16). It might be hypothesized that OCD in
patients with early onset and/or tics is particularly likely to be associated with auto-
antibodies that cross-react with neuronal proteins on the basal ganglia This could
consequently resuit in striatal damage (Swedo et al., 1994).
Although we were unable to find differences in mean levels of 08/17 expression
when the OCD group was stratified into early versus late onset, those with or without
a history of tics, and those with or without a history of different comorbid psychiatric
disorders, the relatively small sample size may well have resulted in type II errors for
these sub-analyses. As more OCD patients are recruited, the problem of insufficient
sample size will be rectified.
Recent work by Peterson and colleagues (2000) has suggested that anti-Streptococcal
antibodies may be associated with attention deficit hyperactivity disorder (ADHD),
rather than with OCD or TS. Again, we were unable to adequately address this
question with our sample, in which only 3 subjects (all in the PD/SP group) also had a
history of ADHD.
Nevertheless, our study did find a significant different in 08/17 expression across the
different groups. 08/17 was numerically, if not statistically, higher in OCD than in
other groups, and there was a significant difference between OCD and other anxiety
disorders (PD/SP group). No clear reason for the relatively decreased expression of
08/17 in this last group is apparent. It would seem that additional work on this marker
in a range of psychiatric disorders remains necessary.
4.6. SUMMARY OF RESULTS OF THE PRESENT STUDY
1. The study showed a positive association between the previously described
COMTINlaIIl polymorphism and OCD in the Afrikaner population.
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2. A novel SNP (COMTP2-1040-CIf) in the COMT gene was identified and
deposited into an SNP database.
3. COM7P2-1040-C/T was shown not to be associated with OCD in the
Afrikaner population. However, this non-significant finding may be the
result of the low information content of this polymorphism.
4. SLC6A4, the gene encoding SHTT, did not reveal any significant
association with OCD in the Afrikaner population.
S. 52C6A 4 also showed no association with OCD when the results of the
present study was pooled with the data generated in an association study
by Bengel et af., 1999.
6. The immunological study showed that the B-lymphocyte surface antigen
marker D8/17 is not significantly associated with OCD in our sample
population. We do, however, speculate that higher 08/17 levels may be
associated with childhood onset OCD or history of tic disorders.
4.7. THE FUTURE OF THIS RESEARCH
The immediate objective for this project is to continue to recruit more patients of
Afrikaner descent to improve the statistical power of these case-control association
studies, thereby improving the ability to detect functional polymorphisms that have a
major to moderate effect on OCD pathogenesis. This is already underway and many
more patients have already been recruited through the MRC Unit on Anxiety and
Stress disorders. By recruiting more patients and control individuals, it would also be
possible to re-evaluate these candidate genes using a new sample of Afrikaner descent
in an effort to replicate the findings of the present study. A larger study sample will
also make a genome-wide scan for OCD susceptibility genes possible. We aim, in
collaboration with the New York State Psychiatric Institute, to do a genome scan in
the future. Furthermore, this project has recruited enough parents of OCD probands,
which makes TOT analysis (section 1.1.2.2) possible and this is a priority in
continuing studies.
In the past year, another researcher in our group has already extended this study to
screen other candidate genes, namely, those encoding the dopamine transporter
(SU'6A3), tyrosine hydroxylase (TH), the serotonin receptor 2A (5HT2A),
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monoamme oxidase A (MAOA) and dopa-decarboxylase (DDCj. Although, many
candidate genes have been screened in this study and some significant findings have
been made (S. Hemmings, personal communication) many other candidate genes
remain to be screened.
It is important that researchers reach a consensus about particular genes and their
allelic variants that are involved in OeD pathogenesis, so that future functional
studies of the proteins they encode may be valid. Reaching such a consensus would
involve many more candidate gene association studies that replicate previously found
association between OeD and a particular gene, as well as new ones.
One of the primary goals in psychiatric genetics is to further the development of
psychopharmacological genetics. Psychopharmacogenetics may improve patient care
by helping the clinician to individualise the pharmacotherapy of each patient based on
their genotype at specific genetic markers (Stoltenberg and Burmeister, 2000). The
present study has gathered a huge amount of genotypic data on this carefully
phenotyped patient sample; therefore this resource could be potentially used to
correlate the generated genotypic data with specific response to pharmacological
treatment. In the future, it is foreseeable that polymorphic markers in candidate genes
screened in this study and studies around the world, as well as in genes still to be
assessed, could help improve diagnoses of OeD, even subclinical OeD. Also, it may
assist in providing patients with more specific, individualised treatment for OeD
based on the genotype at susceptibility loci (Stoltenberg and Burmeister, 2000).
The role ofD8/17 as a possible marker for susceptibility to OeD also warrants further
investigation. As the sample population used in the present study was significantly
different from the sample population used in previous studies, it is important to
reassess the role of 08/17 in the Afrikaner population using a study population
consisting of patients with childhood-onset OeD and a history of comorbid tic
disorders. Replication of the association found in studies of Swedo et ai, (1997) and
Murphy et ai, (1997) using such a sample population would strengthen the present
study hypothesis that D8/17 only serves as a trait marker in patients with childhood-
onset OeD or patients with a history of comorbid tic disorders.
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This study formed part of an integrated approach to identify OCD genetic
susceptibility factors in the Afrikaner population. The data generated in each different
facet of this integrated study may help identify presymptomatic individuals and
facilitate their management. Furthermore, the results may contribute to an
understanding of the molecular pathophysiology of this disabling condition.
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APPENDIX I
BUFFERS, MARKERS AND SOLUTIONS
t BUFFERS
1.1. CELL LYSIS BUFFER
Sucrose 0.32M
Triton-X-lOO 1%
MgCh 5mM
Tris-HC! 10mM
H2O 11
1.2. DNA EXTRACTION BUFFER
NaC! O.lM
Tris-HC! O.OIM
EDTA (pH8) 0.025M
SDS 0.5%
Proteinase K O.lmg/ml
1.3. TBE-BUFFER (tOx stock)
Tris-HC! 0.89M
Boric Acid 0.89M
Na2EDT A (pH8) 20mM
t.4. TE-BUFFER (tOx stock)
TrisOH O.lM
EDTA(pH8) O.OlM
H2O 150ml
1.5. Taq POLYMERASE BUFFER (Bioline)
Ammonium sulphate 160mM
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Tris-Het (pH 8.8)
Tween-20
670mM
0.1%
1.6. QXl BUFFER (Qiagen)
Buffer QXl 500ml
2. SOLUTIONS
2.1. SOLUTIONS FOR POLYACRYLAMIDE GELS
2.1.1. 30% ACRYLAMIDE/0.8% BIS STOCK SOLUTION- FOR SSCP AND
OTHER POLYACRYLAMIDE GELS
Bis-acrylamide
Acrylamide
1.56g
58.5g
Make up solution to 195 ml with H20 after the acrylamide has gone into
solution and store at 4°C.
2.1.2. 10% AMMONIUMPERSULPHATE (APS)
APS
H20
2g
20ml
2.2. SOLUTIONS FOR SILVER STAINING
2.2.1. 0.1% AgN03 (Solution B)
AgN03
H20
19
IL
2.2.2. DEVELOPING SOLUTION (Solution C)
NaOH
NaBH4
Formaldehyde
H20
15g
O.lg
4ml
IL
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3. GELS
3.1. 12% POLYACRYLAMIDE GEL
30 acrylamide/0.8% bis-acrylamide stock 4ml
10xTBE lml
Distilled H2O Sml
APS 80111
TEMED 30111
3.2. 10%MILDLY DENATURING POLYACRYLAMIDE GEL WITH 5%
GLYCEROL
30 acrylamide/0.8% bis-acrylamide stock
10xTBE
Urea
Distilled H20
APS
TEMED
40.Sml
8ml
24g
84ml
1000111
160111
4. LOADING DYES
4.1. BROMOPHENOL BLUE
Bromophenol blue 0.2%(w/v)
Glycerol 50%
Tris (pH8) 10mM
4.2. SSCP LOADING DYE
Formamide 95%
EDTA 20mM
Bromophenol blue 0.01%
Xylene cyanol O.OSg
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5. MOLECULAR WEIGHT MARKER (LAMBDA Pstl)
Bacteriophage Lambda DNA (250llg)
Buffer M (Boerhinger Mannhein)
Pstï (Boerhinger Mannheim)
H20
100111
15111
11111
32111
Incubate at 37°e for 2 hours followed by heat inactivation at 65°e for 5
minutes. Load 2111onto polyacrylamide gels.
6. SOLUTIONS FOR FACS ANALYSIS
6.1. PHOSPHATE BUFFERED SALINE
PBS 10%
6.2. FACS LYSING SOLUTION
Diethylene glycol
Formadldehyde
50%
15%
6.3 FACS FIXING SOLUTION
Formaldehyde 1%
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APPENDIX II
LIST OF SUPPLIERS
Acrylamide
AgN03
Ammonium persulphate
Bis-acrylamide
Boric acid
Bromophenol blue
dGTP
dCTP
dTTP
dATP
EcoRV
EDTA
Ethanol
FACS Lysing Solution
Formamide
Formaldeyde
Gelbond
Glycerol
K-acetate
KCI
Lambda DNA
Mineral oil
NaAc
NaCI
NaOH
NlalII
Oligonucleotide primers
100
Merck
Merck
Merck
Merck
Merck
Merck
Boerhinger Mannheim
Boerhinger Mannheim
Boerhinger Mannheim
Boerhinger Mannheim
Promega
Boerhinger Mannheim
Boerhinger Mannheim
Beckton Dickenson
Merck
Merck
Merck
FMC
Sigma
Merck
Promega
BDH Chemicals
Merck
BDH Chemicals
Sigma
New England Biolabs
Department of
Biochemistry, University
of Cape Town School
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Phenol Merck
PBS Sigma
Proteinase K Sigma
Qiagen Kit Stratagene
SOS Sigma
Taq polymerase Bioline
TEMED Sigma
Tris Merck
Tris-OH Merck
Tris-HCI Merck
Urea BDH Chemicals
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